A biofluid biomarker to reliably diagnose Cerebral Amyloid Angiopathy (CAA) and predict the risk of Amyloid-Related Imaging Abnormalities (ARIA) in Alzheimer’s disease patients.
NeurologyDiagnostic / Biomarker
Technology No.
WIS02-27
Modality
Diagnostic / Biomarker
AI PoS
24%
Strategic Deep Dive
A Biomarker for Cerebral Amyloid Angiopathy (CAA) and Amyloid Related Imaging Abnormality Risk
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 3
AI-Optimized Strategy Track
Time to Market6-7 yrs
PoS24%
Market TierTier 2
Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Why this pivot works
Do not spend early capital proving a vague CNS efficacy story. First prove target engagement through a measurable rescue signal: CSF biomarker, retinal surrogate, peripheral immune marker, or metabolic precursor response that de-risks the brain hypothesis.
Capital discipline
Keep the first package biomarker-led and underpowered for efficacy; buy the right to run a real trial only after target engagement is visible.
Hurdles & Strategic Interventions
Primary BottleneckBlood-brain barrier penetration
AI Strategic InterventionUse delivery engineering, metabolic precursors, or peripheral surrogate endpoints.
Primary BottleneckClinical utility validation
AI Strategic InterventionPackage as a pharma enrichment tool before pursuing broad diagnostic reimbursement.
Buyer Map & IC Decision
Investment CommitteeLicense option
Worth a short exclusive option if diligence confirms IP scope and inventor data quality.
Attractiveness Score71/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Eli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
Biogen
CNS portfolio gap-filling and translational neurology focus.
Roche
CNS diagnostics, biomarkers, and global development scale.
Asset Attractiveness Score
71
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
82/100
Weight 15%Contribution 12 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical Validation Partner
Medpace, Precision for Medicine, Q2 Solutions
Biomarker validation and sample logistics
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Retrospective validation plus one pharma pilot
Use banked samples or existing datasets to prove clinical utility before paying for a prospective study.
Phase 3Prospective enrichment study with Medpace
Run the smallest study that proves the tool improves enrollment, stratification, or decision quality.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Neurology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeEli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeBiogen
CNS portfolio gap-filling and translational neurology focus.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche
CNS diagnostics, biomarkers, and global development scale.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsAlzheimer's diseasea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationAlzheimer's disease
Patients already represented in banked samples, trial datasets, or partner registries.
Study designRetrospective locked-dataset validation followed by one prospective pharma enrichment pilot.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategyRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stagebiomarker validation
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Peripheral or retinal surrogate strategy
Avoid a broad CNS endpoint first; prove mechanism through a measurable proxy.
Trial-enrichment service
Sell into pharma clinical operations before attempting broad reimbursement.
Companion diagnostic option
Attach the technology to a partner drug where patient selection has immediate value.
Final Recommendation
Proceed with repositioning
Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Best next experiment
Run the smallest independent study that validates: Pair the asset with a brain-bioavailable precursor, nasal/local delivery, or exosome/nanoparticle carrier and gate spend on biomarker movement.
Best pharma targets
Eli Lilly, Biogen, Roche
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
An innovative strategy for better diagnosing and safely treating Systemic Lupus Erythematosus, particularly Lupus Nephritis.
ImmunologyInfectious Disease
Technology No.
SIL02-05-10-12-15
Modality
Research platform
AI PoS
30%
Strategic Deep Dive
A Method for Treating and Diagnosing Autoimmune Disease Exacerbated by Host Immune Response to Commensal Bacteria
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market4-6 yrs
PoS30%
Market TierTier 2
Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Why this pivot works
Broad infectious-disease commercialization is brutal. The efficient path is a narrow, high-urgency segment where susceptibility, animal models, and compassionate-use logic can create a fast BD narrative.
Capital discipline
Spend first on microbiology proof and non-dilutive grant leverage; defer expensive GLP tox until the pathogen wedge is obvious.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
GSK
Vaccines and anti-infective infrastructure.
Pfizer
Hospital, anti-infective, and vaccine commercial reach.
Johnson & Johnson
Pathogen-focused development and global health channels.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Immunology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeGSK
Vaccines and anti-infective infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseePfizer
Hospital, anti-infective, and vaccine commercial reach.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeJohnson & Johnson
Pathogen-focused development and global health channels.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsAutoimmune diseasea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationAutoimmune disease
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launchRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Best next experiment
Run the smallest independent study that validates: Run pathogen-panel susceptibility, resistance mapping, and one translational model before any broad tox spend.
Best pharma targets
GSK, Pfizer, Johnson & Johnson
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
A Novel Blood Marker for Prognostication and Treatment of Non-Small Cell Lung Cancer
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market2-4 yrs
PoS45%
Market TierTier 1
Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Why this pivot works
Reimbursement can wait. The cash-efficient path is to sell the technology as a trial-enrichment, patient-stratification, or translational biomarker service to pharma teams that already have trial budgets.
Capital discipline
Use fee-for-service pilots to fund validation; avoid building a regulated diagnostic company before buyer pull is proven.
Hurdles & Strategic Interventions
Primary BottleneckClinical utility validation
AI Strategic InterventionPackage as a pharma enrichment tool before pursuing broad diagnostic reimbursement.
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteePartner outreach
Strong enough to test buyer appetite now while validating the cheapest decisive experiment.
Attractiveness Score74/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
74
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
82/100
Weight 15%Contribution 12 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
84/100
Weight 10%Contribution 8 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
86/100
Weight 10%Contribution 9 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical Validation Partner
Medpace, Precision for Medicine, Q2 Solutions
Biomarker validation and sample logistics
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Retrospective validation plus one pharma pilot
Use banked samples or existing datasets to prove clinical utility before paying for a prospective study.
Phase 3Prospective enrichment study with Medpace
Run the smallest study that proves the tool improves enrollment, stratification, or decision quality.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsNon-small cell lung cancera biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationNon-small cell lung cancer
Patients already represented in banked samples, trial datasets, or partner registries.
Study designRetrospective locked-dataset validation followed by one prospective pharma enrichment pilot.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Monetize first as a pharma enrichment engine, not a reimbursed diagnosticRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stagebiomarker validation
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Trial-enrichment service
Sell into pharma clinical operations before attempting broad reimbursement.
Companion diagnostic option
Attach the technology to a partner drug where patient selection has immediate value.
Final Recommendation
Proceed
Strong enough to test buyer appetite now while validating the cheapest decisive experiment. The most investable version is: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Best next experiment
Run the smallest independent study that validates: Package the model or assay with a locked validation dataset, CLIA/service workflow, and one sponsor-ready use case.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
There is no scalable platform today that can efficiently generate peptide-specific binders to intracellular cancer targets and translate them into broadly applicable cell therapies across diverse HLA types.
OncologyBiologicCell/Gene TherapyBiomanufacturing
Technology No.
YAR01-09, YAR01-20
Modality
Biologic
AI PoS
23%
Strategic Deep Dive
A Scalable Platform for Cross-HLA CAR-T Targeting of Intracellular Cancer Drivers
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 2
AI-Optimized Strategy Track
Time to Market5-7 yrs
PoS23%
Market TierTier 2
Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero
Why this pivot works
The scientific upside is high, but manufacturing can consume the company. Pick one genetically crisp patient segment, one potency assay, and one CDMO process before trying to build a platform narrative.
Capital discipline
Avoid internal manufacturing buildout; spend on binder validation, potency assay reproducibility, and a narrow IND package.
Hurdles & Strategic Interventions
Primary BottleneckManufacturing complexity
AI Strategic InterventionMatch early with a cell/gene CDMO and lock a scalable release assay.
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeLicense option
Worth a short exclusive option if diligence confirms IP scope and inventor data quality.
Attractiveness Score71/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Manufacturing and oncology BD infrastructure already exists.
Regeneron
Deep oncology biologics and T-cell engager adjacency.
Asset Attractiveness Score
71
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
80/100
Weight 15%Contribution 12 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical Validation Partner
Medpace, Precision for Medicine, Q2 Solutions
Biomarker validation and sample logistics
Cell/Gene CDMO
Lonza, Catalent, Thermo Fisher
Vector, cell processing, potency assays
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Binder, potency assay, and CMC feasibility with Charles River
Gate the program on reproducible potency and manufacturability before expensive IND-enabling tox.
Phase 3Orphan Phase 1b signal trial with Medpace
Target a genetically defined cohort where a small response signal can trigger pharma partnering.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeGilead / Kite
Manufacturing and oncology BD infrastructure already exists.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRegeneron
Deep oncology biologics and T-cell engager adjacency.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsCancera biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationCancer
Molecularly defined patients with target expression, immune context, or resistance biology.
Study designBiomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zeroRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Final Recommendation
Proceed with repositioning
Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero
Best next experiment
Run the smallest independent study that validates: Use a centralized CDMO, lock the release assay early, and design the first trial around tumor-antigen evidence rather than broad basket ambition.
Best pharma targets
BMS / 2seventy, Gilead / Kite, Regeneron
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
A unique platform that combines comprehensive tumor antigen discovery with direct validation of HLA-presented peptides, bridging the gap between predicted targets and clinically actionable opportunities in immunotherapy and diagnostics.
An End-to-End Platform for Discovering and Validating Clinically Actionable Tumor Antigens
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 2
AI-Optimized Strategy Track
Time to Market5-7 yrs
PoS23%
Market TierTier 2
Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero
Why this pivot works
The scientific upside is high, but manufacturing can consume the company. Pick one genetically crisp patient segment, one potency assay, and one CDMO process before trying to build a platform narrative.
Capital discipline
Avoid internal manufacturing buildout; spend on binder validation, potency assay reproducibility, and a narrow IND package.
Hurdles & Strategic Interventions
Primary BottleneckManufacturing complexity
AI Strategic InterventionMatch early with a cell/gene CDMO and lock a scalable release assay.
Primary BottleneckClinical utility validation
AI Strategic InterventionPackage as a pharma enrichment tool before pursuing broad diagnostic reimbursement.
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeLicense option
Worth a short exclusive option if diligence confirms IP scope and inventor data quality.
Attractiveness Score73/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Manufacturing and oncology BD infrastructure already exists.
Regeneron
Deep oncology biologics and T-cell engager adjacency.
Asset Attractiveness Score
73
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
82/100
Weight 15%Contribution 12 pts
Differentiation
How clearly the technology can be positioned as different.
80/100
Weight 15%Contribution 12 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical Validation Partner
Medpace, Precision for Medicine, Q2 Solutions
Biomarker validation and sample logistics
Cell/Gene CDMO
Lonza, Catalent, Thermo Fisher
Vector, cell processing, potency assays
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Retrospective validation plus one pharma pilot
Use banked samples or existing datasets to prove clinical utility before paying for a prospective study.
Phase 3Prospective enrichment study with Medpace
Run the smallest study that proves the tool improves enrollment, stratification, or decision quality.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeGilead / Kite
Manufacturing and oncology BD infrastructure already exists.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRegeneron
Deep oncology biologics and T-cell engager adjacency.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa molecularly selected tumor segment where a small proof-of-mechanism study is crediblea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa molecularly selected tumor segment where a small proof-of-mechanism study is credible
Patients already represented in banked samples, trial datasets, or partner registries.
Study designRetrospective locked-dataset validation followed by one prospective pharma enrichment pilot.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zeroRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stagebiomarker validation
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Trial-enrichment service
Sell into pharma clinical operations before attempting broad reimbursement.
Companion diagnostic option
Attach the technology to a partner drug where patient selection has immediate value.
Final Recommendation
Proceed with repositioning
Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero
Best next experiment
Run the smallest independent study that validates: Use a centralized CDMO, lock the release assay early, and design the first trial around tumor-antigen evidence rather than broad basket ambition.
Best pharma targets
BMS / 2seventy, Gilead / Kite, Regeneron
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score66/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Novartis
Broad modality appetite and academic-origin BD history.
Takeda
Translational science focus and partnership-friendly structure.
Sanofi
Immunology, rare disease, and platform-technology BD appetite.
Asset Attractiveness Score
66
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
62/100
Weight 15%Contribution 9 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp specialty therapeutics wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeNovartis
Broad modality appetite and academic-origin BD history.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeTakeda
Translational science focus and partnership-friendly structure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeSanofi
Immunology, rare disease, and platform-technology BD appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsthe narrowest patient segment where the mechanism can create a measurable signal quicklya biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationthe narrowest patient segment where the mechanism can create a measurable signal quickly
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Novartis, Takeda, Sanofi
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Innovative, efficacious, and improved treatment option for Acute Myeloid Leukemia (AML) and Glioblastoma (GBM).
OncologyImmunologySmall MoleculeBiologic
Technology No.
KOI01-16
Modality
Small Molecule
AI PoS
22%
Strategic Deep Dive
Anti-CD97 Antibody-Drug Conjugates for the Treatment of AML and GBM
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
Hurdles & Strategic Interventions
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeLicense option
Worth a short exclusive option if diligence confirms IP scope and inventor data quality.
Attractiveness Score71/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
71
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
80/100
Weight 15%Contribution 12 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsAcute myeloid leukemiaa biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationAcute myeloid leukemia
Molecularly defined patients with target expression, immune context, or resistance biology.
Study designBiomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Final Recommendation
Proceed with repositioning
Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
New anti-CD99 antibodies for the treatment of rare hematological malignancies
Oncology
Technology No.
KOI01-05
Modality
Research platform
AI PoS
22%
Strategic Deep Dive
Anti-CD99 Antibodies Cytotoxic to Leukemia
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
Hurdles & Strategic Interventions
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa molecularly selected tumor segment where a small proof-of-mechanism study is crediblea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa molecularly selected tumor segment where a small proof-of-mechanism study is credible
Molecularly defined patients with target expression, immune context, or resistance biology.
Study designBiomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Innovative, efficacious and complementary non lipoprotein-lowering treatments for atherosclerosis.
Biologic
Technology No.
GOL05-04
Modality
Biologic
AI PoS
22%
Strategic Deep Dive
Apolipoprotein B Peptide Mimics for Atherosclerosis Treatment
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score66/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Novartis
Broad modality appetite and academic-origin BD history.
Takeda
Translational science focus and partnership-friendly structure.
Sanofi
Immunology, rare disease, and platform-technology BD appetite.
Asset Attractiveness Score
66
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
62/100
Weight 15%Contribution 9 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp specialty therapeutics wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeNovartis
Broad modality appetite and academic-origin BD history.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeTakeda
Translational science focus and partnership-friendly structure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeSanofi
Immunology, rare disease, and platform-technology BD appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsthe narrowest patient segment where the mechanism can create a measurable signal quicklya biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationthe narrowest patient segment where the mechanism can create a measurable signal quickly
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Novartis, Takeda, Sanofi
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
A novel disease-modifying treatment of inflammatory bowel diseases that doesn't compromise the patient immune system.
ImmunologyInflammationSmall Molecule
Technology No.
CAD01-05
Modality
Small Molecule
AI PoS
22%
Strategic Deep Dive
Apoptosis Inhibitor 5 (API5)-based Therapeutic for the Treatment of Inflammatory Bowel Diseases
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Novartis
Broad modality appetite and academic-origin BD history.
Takeda
Translational science focus and partnership-friendly structure.
Sanofi
Immunology, rare disease, and platform-technology BD appetite.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Immunology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeNovartis
Broad modality appetite and academic-origin BD history.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeTakeda
Translational science focus and partnership-friendly structure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeSanofi
Immunology, rare disease, and platform-technology BD appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsInflammatory diseasea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationInflammatory disease
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Novartis, Takeda, Sanofi
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Potent, specific, modular, cost-effective, and synthetically-accessible agents for cytotoxic DNA cleavage.
OncologyInfectious DiseaseSmall Molecule
Technology No.
DIA01-02
Modality
Small Molecule
AI PoS
30%
Strategic Deep Dive
Aryl-Diazonium Analogues as Potent DNA Cleavage Agents for Treating Cancer and Bacterial Infections
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market4-6 yrs
PoS30%
Market TierTier 2
Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Why this pivot works
Broad infectious-disease commercialization is brutal. The efficient path is a narrow, high-urgency segment where susceptibility, animal models, and compassionate-use logic can create a fast BD narrative.
Capital discipline
Spend first on microbiology proof and non-dilutive grant leverage; defer expensive GLP tox until the pathogen wedge is obvious.
Hurdles & Strategic Interventions
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsCancera biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationCancer
Molecularly defined patients with target expression, immune context, or resistance biology.
Study designBiomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launchRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Best next experiment
Run the smallest independent study that validates: Run pathogen-panel susceptibility, resistance mapping, and one translational model before any broad tox spend.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Effective topical wound healing agent that stimulate tissue regeneration through diverse biological activities that correct multiple defects of the wound healing process for the treatment of chronic wounds, such as diabetic foot ulcers (DFUs) and to enhance the rate and quality of healing of acute wounds (burns, injury, surgery).
Small MoleculeBiologicDrug Delivery
Technology No.
GOL01-10
Modality
Small Molecule
AI PoS
28%
Strategic Deep Dive
Biomimetic Nanofibers Electrospun with Calreticulin as Wound Healing Agents
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market5-6 yrs
PoS28%
Market TierTier 2
Turn delivery into the asset by choosing a toxicity-sensitive local indication
Why this pivot works
A delivery technology wins when it solves a painful tradeoff: high local exposure with low systemic burden. Pick an indication where reduced dose, fewer adverse events, or easier administration is the buyer's actual reason to care.
Capital discipline
Use a validated payload and small PK package; do not fund broad platform claims until one local-use case works.
Hurdles & Strategic Interventions
Primary BottleneckFormulation and biodistribution risk
AI Strategic InterventionMove to localized administration and validate exposure with a focused PK package.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score68/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Novartis
Broad modality appetite and academic-origin BD history.
Takeda
Translational science focus and partnership-friendly structure.
Sanofi
Immunology, rare disease, and platform-technology BD appetite.
Asset Attractiveness Score
68
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
62/100
Weight 15%Contribution 9 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
80/100
Weight 15%Contribution 12 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Turn delivery into the asset by choosing a toxicity-sensitive local indication. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp specialty therapeutics wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeNovartis
Broad modality appetite and academic-origin BD history.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeTakeda
Translational science focus and partnership-friendly structure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeSanofi
Immunology, rare disease, and platform-technology BD appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsthe narrowest patient segment where the mechanism can create a measurable signal quicklya biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationthe narrowest patient segment where the mechanism can create a measurable signal quickly
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Turn delivery into the asset by choosing a toxicity-sensitive local indicationRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Turn delivery into the asset by choosing a toxicity-sensitive local indication
New delivery route
Pair the delivery system with a known payload and prove exposure advantage in a local indication.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Turn delivery into the asset by choosing a toxicity-sensitive local indication
Best next experiment
Run the smallest independent study that validates: Run biodistribution and local tolerability first, then attach the platform to a known active payload instead of inventing a new drug story.
Best pharma targets
Novartis, Takeda, Sanofi
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
New and efficacious versions of fibroblast growth factor 21 (FGF21) for metabolic liver diseases
Cardiometabolic
Technology No.
MOH01-03
Modality
Research platform
AI PoS
22%
Strategic Deep Dive
Chimeric FGF21: Treatment of NAFLD, NASH and Hepatic Steatosis
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Novartis
Broad modality appetite and academic-origin BD history.
Takeda
Translational science focus and partnership-friendly structure.
Sanofi
Immunology, rare disease, and platform-technology BD appetite.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Cardiometabolic wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeNovartis
Broad modality appetite and academic-origin BD history.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeTakeda
Translational science focus and partnership-friendly structure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeSanofi
Immunology, rare disease, and platform-technology BD appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsLiver diseasea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationLiver disease
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Novartis, Takeda, Sanofi
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Clinical Prognostic Models for Stage II Melanoma Using Tumor miRNA Signatures
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 3
AI-Optimized Strategy Track
Time to Market2-4 yrs
PoS45%
Market TierTier 1
Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Why this pivot works
Reimbursement can wait. The cash-efficient path is to sell the technology as a trial-enrichment, patient-stratification, or translational biomarker service to pharma teams that already have trial budgets.
Capital discipline
Use fee-for-service pilots to fund validation; avoid building a regulated diagnostic company before buyer pull is proven.
Hurdles & Strategic Interventions
Primary BottleneckClinical utility validation
AI Strategic InterventionPackage as a pharma enrichment tool before pursuing broad diagnostic reimbursement.
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteePartner outreach
Strong enough to test buyer appetite now while validating the cheapest decisive experiment.
Attractiveness Score74/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
74
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
82/100
Weight 15%Contribution 12 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
84/100
Weight 10%Contribution 8 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
86/100
Weight 10%Contribution 9 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical Validation Partner
Medpace, Precision for Medicine, Q2 Solutions
Biomarker validation and sample logistics
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Retrospective validation plus one pharma pilot
Use banked samples or existing datasets to prove clinical utility before paying for a prospective study.
Phase 3Prospective enrichment study with Medpace
Run the smallest study that proves the tool improves enrollment, stratification, or decision quality.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa molecularly selected tumor segment where a small proof-of-mechanism study is crediblea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa molecularly selected tumor segment where a small proof-of-mechanism study is credible
Patients already represented in banked samples, trial datasets, or partner registries.
Study designRetrospective locked-dataset validation followed by one prospective pharma enrichment pilot.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Monetize first as a pharma enrichment engine, not a reimbursed diagnosticRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stagebiomarker validation
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Trial-enrichment service
Sell into pharma clinical operations before attempting broad reimbursement.
Companion diagnostic option
Attach the technology to a partner drug where patient selection has immediate value.
Final Recommendation
Proceed
Strong enough to test buyer appetite now while validating the cheapest decisive experiment. The most investable version is: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Best next experiment
Run the smallest independent study that validates: Package the model or assay with a locked validation dataset, CLIA/service workflow, and one sponsor-ready use case.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Innovative, efficacious, and novel treatment strategy for overcoming resistance to BH3 mimetics in Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)
OncologyAI / ML
Technology No.
AIF01-10
Modality
AI / ML
AI PoS
45%
Strategic Deep Dive
Combination Therapies Against the Apoptosis Sensitizing Target OPA1 for Overcoming Therapy Resistance in Acute Myeloid Leukemia
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market2-4 yrs
PoS45%
Market TierTier 1
Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Why this pivot works
Reimbursement can wait. The cash-efficient path is to sell the technology as a trial-enrichment, patient-stratification, or translational biomarker service to pharma teams that already have trial budgets.
Capital discipline
Use fee-for-service pilots to fund validation; avoid building a regulated diagnostic company before buyer pull is proven.
Hurdles & Strategic Interventions
Primary BottleneckClinical utility validation
AI Strategic InterventionPackage as a pharma enrichment tool before pursuing broad diagnostic reimbursement.
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeLicense option
Worth a short exclusive option if diligence confirms IP scope and inventor data quality.
Attractiveness Score72/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
72
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
84/100
Weight 10%Contribution 8 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
86/100
Weight 10%Contribution 9 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Retrospective validation plus one pharma pilot
Use banked samples or existing datasets to prove clinical utility before paying for a prospective study.
Phase 3Prospective enrichment study with IQVIA
Run the smallest study that proves the tool improves enrollment, stratification, or decision quality.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsAcute myeloid leukemiaa biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationAcute myeloid leukemia
Patients already represented in banked samples, trial datasets, or partner registries.
Study designRetrospective locked-dataset validation followed by one prospective pharma enrichment pilot.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Monetize first as a pharma enrichment engine, not a reimbursed diagnosticRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stagebiomarker validation
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Trial-enrichment service
Sell into pharma clinical operations before attempting broad reimbursement.
Companion diagnostic option
Attach the technology to a partner drug where patient selection has immediate value.
Final Recommendation
Proceed with repositioning
Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Best next experiment
Run the smallest independent study that validates: Package the model or assay with a locked validation dataset, CLIA/service workflow, and one sponsor-ready use case.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
A rapid, safe, and tunable method of weight loss and metabolic regulation in the context of obesity and associated metabolic disorder treatment.
Cardiometabolic
Technology No.
LIT01-56
Modality
Research platform
AI PoS
22%
Strategic Deep Dive
Cysteine Depletion as a Treatment for Obesity and Associated Metabolic Disorders
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Novartis
Broad modality appetite and academic-origin BD history.
Takeda
Translational science focus and partnership-friendly structure.
Sanofi
Immunology, rare disease, and platform-technology BD appetite.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Cardiometabolic wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeNovartis
Broad modality appetite and academic-origin BD history.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeTakeda
Translational science focus and partnership-friendly structure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeSanofi
Immunology, rare disease, and platform-technology BD appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsthe narrowest patient segment where the mechanism can create a measurable signal quicklya biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationthe narrowest patient segment where the mechanism can create a measurable signal quickly
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Novartis, Takeda, Sanofi
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Innovative therapies to overcome resistance to KRAS G12C inhibitors (G12Cis) in KRAS-mutant cancers.
OncologySmall Molecule
Technology No.
NEE02-05
Modality
Small Molecule
AI PoS
22%
Strategic Deep Dive
Drug Targets for Overcoming Resistance to KRAS G12C Inhibitors (G12Cis) in Cancer
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
Hurdles & Strategic Interventions
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsCancera biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationCancer
Molecularly defined patients with target expression, immune context, or resistance biology.
Study designBiomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
New efficacious TNFα inhibitors for the treatment of Rheumatoid arthritis and other autoimmune diseases.
ImmunologyInflammationSmall Molecule
Technology No.
LIU02-03
Modality
Small Molecule
AI PoS
22%
Strategic Deep Dive
Engineered Progranulin: A Promising Therapeutic Approach for Autoimmune Diseases
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Novartis
Broad modality appetite and academic-origin BD history.
Takeda
Translational science focus and partnership-friendly structure.
Sanofi
Immunology, rare disease, and platform-technology BD appetite.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Immunology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeNovartis
Broad modality appetite and academic-origin BD history.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeTakeda
Translational science focus and partnership-friendly structure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeSanofi
Immunology, rare disease, and platform-technology BD appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsAutoimmune diseasea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationAutoimmune disease
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Novartis, Takeda, Sanofi
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Novel therapeutic approach to reverse or prevent the progression of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD)
Neurology
Technology No.
MAZ02-03
Modality
Research platform
AI PoS
24%
Strategic Deep Dive
Enhancing Neuronal Resistance to Neurodegeneration
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-7 yrs
PoS24%
Market TierTier 2
Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Why this pivot works
Do not spend early capital proving a vague CNS efficacy story. First prove target engagement through a measurable rescue signal: CSF biomarker, retinal surrogate, peripheral immune marker, or metabolic precursor response that de-risks the brain hypothesis.
Capital discipline
Keep the first package biomarker-led and underpowered for efficacy; buy the right to run a real trial only after target engagement is visible.
Hurdles & Strategic Interventions
Primary BottleneckBlood-brain barrier penetration
AI Strategic InterventionUse delivery engineering, metabolic precursors, or peripheral surrogate endpoints.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Eli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
Biogen
CNS portfolio gap-filling and translational neurology focus.
Roche
CNS diagnostics, biomarkers, and global development scale.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Neurology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeEli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeBiogen
CNS portfolio gap-filling and translational neurology focus.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche
CNS diagnostics, biomarkers, and global development scale.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa biomarker-defined neuroinflammation or neurodegeneration subgroupa biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa biomarker-defined neuroinflammation or neurodegeneration subgroup
Patients stratified by CSF, imaging, genetic, retinal, inflammatory, or metabolic markers.
Study designMechanism-first biomarker study before any broad symptomatic endpoint trial.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategyRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Peripheral or retinal surrogate strategy
Avoid a broad CNS endpoint first; prove mechanism through a measurable proxy.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Best next experiment
Run the smallest independent study that validates: Pair the asset with a brain-bioavailable precursor, nasal/local delivery, or exosome/nanoparticle carrier and gate spend on biomarker movement.
Best pharma targets
Eli Lilly, Biogen, Roche
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
An innovative and targeted approache to treat cancer and autoimmune, inflammatory, and infectious diseases
OncologyImmunologyInflammationInfectious Disease
Technology No.
MOH02-07
Modality
Research platform
AI PoS
30%
Strategic Deep Dive
Epitranscriptomic Modulation of Type I IFN Pathway to Treat Cancer and Autoimmune, Inflammatory, and Infectious Diseases
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market4-6 yrs
PoS30%
Market TierTier 2
Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Why this pivot works
Broad infectious-disease commercialization is brutal. The efficient path is a narrow, high-urgency segment where susceptibility, animal models, and compassionate-use logic can create a fast BD narrative.
Capital discipline
Spend first on microbiology proof and non-dilutive grant leverage; defer expensive GLP tox until the pathogen wedge is obvious.
Hurdles & Strategic Interventions
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsAutoimmune diseasea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationAutoimmune disease
Molecularly defined patients with target expression, immune context, or resistance biology.
Study designBiomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launchRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Best next experiment
Run the smallest independent study that validates: Run pathogen-panel susceptibility, resistance mapping, and one translational model before any broad tox spend.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Innovative and efficacious treatments for chronic kidney disease and phosphate-wasting diseases.
CardiometabolicBiologic
Technology No.
MOH01-02
Modality
Biologic
AI PoS
22%
Strategic Deep Dive
FGF23 Ligand Trap: New Biologic for Treating Kidney Diseases
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Novartis
Broad modality appetite and academic-origin BD history.
Takeda
Translational science focus and partnership-friendly structure.
Sanofi
Immunology, rare disease, and platform-technology BD appetite.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Cardiometabolic wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeNovartis
Broad modality appetite and academic-origin BD history.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeTakeda
Translational science focus and partnership-friendly structure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeSanofi
Immunology, rare disease, and platform-technology BD appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsKidney diseasea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationKidney disease
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Novartis, Takeda, Sanofi
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
The first therapeutic strategy designed to selectively disrupt platelet–tumor cell interactions, a key driver of cancer metastasis and post-surgical tumor spread.
OncologyImmunologyBiologic
Technology No.
WIS02-12
Modality
Biologic
AI PoS
42%
Strategic Deep Dive
First-in-Class Antibody Therapy Targeting Platelet-Driven Cancer Metastasis
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market2-4 yrs
PoS42%
Market TierTier 1
Use the device as a low-cost clinical workflow wedge, not a full therapeutic platform
Why this pivot works
Start with the narrowest procedure or diagnostic moment where the device changes a measurable decision: fewer repeat visits, faster detection, cleaner sampling, or reduced operator variability. Avoid building a broad hardware company until a paid workflow exists.
Capital discipline
Preserve cash by using off-the-shelf components, one KOL site, and a service-style pilot before tooling for scale.
Hurdles & Strategic Interventions
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeLicense option
Worth a short exclusive option if diligence confirms IP scope and inventor data quality.
Attractiveness Score72/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
72
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
84/100
Weight 10%Contribution 8 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
86/100
Weight 10%Contribution 9 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Use the device as a low-cost clinical workflow wedge, not a full therapeutic platform. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsCancera biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationCancer
Molecularly defined patients with target expression, immune context, or resistance biology.
Study designBiomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Use the device as a low-cost clinical workflow wedge, not a full therapeutic platformRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Use the device as a low-cost clinical workflow wedge, not a full therapeutic platform
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Final Recommendation
Proceed with repositioning
Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Use the device as a low-cost clinical workflow wedge, not a full therapeutic platform
Best next experiment
Run the smallest independent study that validates: Run a usability + analytical validation package first, then pursue a small prospective study at one high-volume clinical site.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
A first-in-class vaccine approach to prevent or delay fatal, transmissible prion diseases in humans and animals.
NeurologyBiologic
Technology No.
WIS02-20
Modality
Biologic
AI PoS
24%
Strategic Deep Dive
First-in-Class Vaccine Platform to Halt Prion Transmission Across Species
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market7-9 yrs
PoS12%
Market TierTier 3
AI-Optimized Strategy Track
Time to Market6-7 yrs
PoS24%
Market TierTier 2
Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Why this pivot works
Do not spend early capital proving a vague CNS efficacy story. First prove target engagement through a measurable rescue signal: CSF biomarker, retinal surrogate, peripheral immune marker, or metabolic precursor response that de-risks the brain hypothesis.
Capital discipline
Keep the first package biomarker-led and underpowered for efficacy; buy the right to run a real trial only after target engagement is visible.
Hurdles & Strategic Interventions
Primary BottleneckBlood-brain barrier penetration
AI Strategic InterventionUse delivery engineering, metabolic precursors, or peripheral surrogate endpoints.
Buyer Map & IC Decision
Investment CommitteeLicense option
Worth a short exclusive option if diligence confirms IP scope and inventor data quality.
Attractiveness Score71/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Eli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
Biogen
CNS portfolio gap-filling and translational neurology focus.
Roche
CNS diagnostics, biomarkers, and global development scale.
Asset Attractiveness Score
71
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
70/100
Weight 10%Contribution 7 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical Validation Partner
Medpace, Precision for Medicine, Q2 Solutions
Biomarker validation and sample logistics
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with Medpace
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Neurology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeEli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeBiogen
CNS portfolio gap-filling and translational neurology focus.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche
CNS diagnostics, biomarkers, and global development scale.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa biomarker-defined neuroinflammation or neurodegeneration subgroupa biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa biomarker-defined neuroinflammation or neurodegeneration subgroup
Patients stratified by CSF, imaging, genetic, retinal, inflammatory, or metabolic markers.
Study designMechanism-first biomarker study before any broad symptomatic endpoint trial.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategyRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Peripheral or retinal surrogate strategy
Avoid a broad CNS endpoint first; prove mechanism through a measurable proxy.
Final Recommendation
Proceed with repositioning
Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Best next experiment
Run the smallest independent study that validates: Pair the asset with a brain-bioavailable precursor, nasal/local delivery, or exosome/nanoparticle carrier and gate spend on biomarker movement.
Best pharma targets
Eli Lilly, Biogen, Roche
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Gene-signature for Predicting Immune-Related Adverse Events (irAEs) After Immune Checkpoint Inhibitor (ICI) Treatment
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market2-4 yrs
PoS42%
Market TierTier 1
Use the device as a low-cost clinical workflow wedge, not a full therapeutic platform
Why this pivot works
Start with the narrowest procedure or diagnostic moment where the device changes a measurable decision: fewer repeat visits, faster detection, cleaner sampling, or reduced operator variability. Avoid building a broad hardware company until a paid workflow exists.
Capital discipline
Preserve cash by using off-the-shelf components, one KOL site, and a service-style pilot before tooling for scale.
Hurdles & Strategic Interventions
Primary BottleneckClinical utility validation
AI Strategic InterventionPackage as a pharma enrichment tool before pursuing broad diagnostic reimbursement.
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteePartner outreach
Strong enough to test buyer appetite now while validating the cheapest decisive experiment.
Attractiveness Score76/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
76
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
82/100
Weight 15%Contribution 12 pts
Differentiation
How clearly the technology can be positioned as different.
80/100
Weight 15%Contribution 12 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
84/100
Weight 10%Contribution 8 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
86/100
Weight 10%Contribution 9 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical Validation Partner
Medpace, Precision for Medicine, Q2 Solutions
Biomarker validation and sample logistics
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Use the device as a low-cost clinical workflow wedge, not a full therapeutic platform. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Retrospective validation plus one pharma pilot
Use banked samples or existing datasets to prove clinical utility before paying for a prospective study.
Phase 3Prospective enrichment study with Medpace
Run the smallest study that proves the tool improves enrollment, stratification, or decision quality.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa molecularly selected tumor segment where a small proof-of-mechanism study is crediblea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa molecularly selected tumor segment where a small proof-of-mechanism study is credible
Patients already represented in banked samples, trial datasets, or partner registries.
Study designRetrospective locked-dataset validation followed by one prospective pharma enrichment pilot.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Use the device as a low-cost clinical workflow wedge, not a full therapeutic platformRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stagebiomarker validation
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Use the device as a low-cost clinical workflow wedge, not a full therapeutic platform
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Trial-enrichment service
Sell into pharma clinical operations before attempting broad reimbursement.
Companion diagnostic option
Attach the technology to a partner drug where patient selection has immediate value.
Final Recommendation
Proceed
Strong enough to test buyer appetite now while validating the cheapest decisive experiment. The most investable version is: Use the device as a low-cost clinical workflow wedge, not a full therapeutic platform
Best next experiment
Run the smallest independent study that validates: Run a usability + analytical validation package first, then pursue a small prospective study at one high-volume clinical site.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
An innovative strategy for identifying, enriching and utilizing gut commensal microbes to colonize tumors and facilitate tumor clearance.
Oncology
Technology No.
SCH16-01
Modality
Research platform
AI PoS
22%
Strategic Deep Dive
Gut Commensal Microbes as Tumor Targeted Therapeutics
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
Hurdles & Strategic Interventions
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa molecularly selected tumor segment where a small proof-of-mechanism study is crediblea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa molecularly selected tumor segment where a small proof-of-mechanism study is credible
Molecularly defined patients with target expression, immune context, or resistance biology.
Study designBiomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
An Innovative and efficacious therapeutic strategy to prevent and/or treat AD and other dementias.
Biologic
Technology No.
WIS02-26
Modality
Biologic
AI PoS
22%
Strategic Deep Dive
Hydrophobically Interspaced, Charged Peptides for the Treatment and Prevention of Dementia
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score66/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Novartis
Broad modality appetite and academic-origin BD history.
Takeda
Translational science focus and partnership-friendly structure.
Sanofi
Immunology, rare disease, and platform-technology BD appetite.
Asset Attractiveness Score
66
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
62/100
Weight 15%Contribution 9 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp specialty therapeutics wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeNovartis
Broad modality appetite and academic-origin BD history.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeTakeda
Translational science focus and partnership-friendly structure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeSanofi
Immunology, rare disease, and platform-technology BD appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsthe narrowest patient segment where the mechanism can create a measurable signal quicklya biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationthe narrowest patient segment where the mechanism can create a measurable signal quickly
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Novartis, Takeda, Sanofi
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
A first-in-class small-molecule strategy designed to convert immunologically “cold” pancreatic tumors into immune-responsive tumors by activating endogenous inflammatory signaling.
OncologyImmunologyInflammationCardiometabolic
Technology No.
POS01-11
Modality
Research platform
AI PoS
22%
Strategic Deep Dive
Immunometabolic Reprogramming Platform to Sensitize Pancreatic Cancer to Anti-Tumor Immunity
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 3
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
Hurdles & Strategic Interventions
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical Validation Partner
Medpace, Precision for Medicine, Q2 Solutions
Biomarker validation and sample logistics
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with Medpace
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsInflammatory diseasea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationInflammatory disease
Molecularly defined patients with target expression, immune context, or resistance biology.
Study designBiomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Mechanistically-defined, localized, and repurposed immuno‑metabolic precision therapy that overcomes age‑related resistance to immune checkpoint and targeted therapies in non‑small cell lung cancer (NSCLC).
Inhaled Lipid‑Reducing Agents to Restore Anti‑Tumor Immunity and Enhance Immunotherapy in Aged Lung Cancer Patients
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market5-6 yrs
PoS28%
Market TierTier 2
Turn delivery into the asset by choosing a toxicity-sensitive local indication
Why this pivot works
A delivery technology wins when it solves a painful tradeoff: high local exposure with low systemic burden. Pick an indication where reduced dose, fewer adverse events, or easier administration is the buyer's actual reason to care.
Capital discipline
Use a validated payload and small PK package; do not fund broad platform claims until one local-use case works.
Hurdles & Strategic Interventions
Primary BottleneckFormulation and biodistribution risk
AI Strategic InterventionMove to localized administration and validate exposure with a focused PK package.
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeLicense option
Worth a short exclusive option if diligence confirms IP scope and inventor data quality.
Attractiveness Score71/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
71
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
80/100
Weight 15%Contribution 12 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Turn delivery into the asset by choosing a toxicity-sensitive local indication. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsLung cancera biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationLung cancer
Molecularly defined patients with target expression, immune context, or resistance biology.
Study designBiomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Turn delivery into the asset by choosing a toxicity-sensitive local indicationRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Turn delivery into the asset by choosing a toxicity-sensitive local indication
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
New delivery route
Pair the delivery system with a known payload and prove exposure advantage in a local indication.
Final Recommendation
Proceed with repositioning
Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Turn delivery into the asset by choosing a toxicity-sensitive local indication
Best next experiment
Run the smallest independent study that validates: Run biodistribution and local tolerability first, then attach the platform to a known active payload instead of inventing a new drug story.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Efficacious treatment for chronic neurological diseases and acute central nervous system (CNS) injury.
NeurologyCardiometabolicDrug Delivery
Technology No.
LID01-01
Modality
Drug Delivery
AI PoS
24%
Strategic Deep Dive
Inhibition of Astrocyte-Derived Neurotoxic Lipid for Treatment of Neurological Injury and Diseases
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-7 yrs
PoS24%
Market TierTier 2
Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Why this pivot works
Do not spend early capital proving a vague CNS efficacy story. First prove target engagement through a measurable rescue signal: CSF biomarker, retinal surrogate, peripheral immune marker, or metabolic precursor response that de-risks the brain hypothesis.
Capital discipline
Keep the first package biomarker-led and underpowered for efficacy; buy the right to run a real trial only after target engagement is visible.
Hurdles & Strategic Interventions
Primary BottleneckBlood-brain barrier penetration
AI Strategic InterventionUse delivery engineering, metabolic precursors, or peripheral surrogate endpoints.
Primary BottleneckFormulation and biodistribution risk
AI Strategic InterventionMove to localized administration and validate exposure with a focused PK package.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Eli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
Biogen
CNS portfolio gap-filling and translational neurology focus.
Roche
CNS diagnostics, biomarkers, and global development scale.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Neurology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeEli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeBiogen
CNS portfolio gap-filling and translational neurology focus.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche
CNS diagnostics, biomarkers, and global development scale.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa biomarker-defined neuroinflammation or neurodegeneration subgroupa biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa biomarker-defined neuroinflammation or neurodegeneration subgroup
Patients stratified by CSF, imaging, genetic, retinal, inflammatory, or metabolic markers.
Study designMechanism-first biomarker study before any broad symptomatic endpoint trial.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategyRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Peripheral or retinal surrogate strategy
Avoid a broad CNS endpoint first; prove mechanism through a measurable proxy.
New delivery route
Pair the delivery system with a known payload and prove exposure advantage in a local indication.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Best next experiment
Run the smallest independent study that validates: Pair the asset with a brain-bioavailable precursor, nasal/local delivery, or exosome/nanoparticle carrier and gate spend on biomarker movement.
Best pharma targets
Eli Lilly, Biogen, Roche
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
A non-surgical method for effectively treating both oral cancer and related pain.
OncologyNeurologyAI / ML
Technology No.
LAC01-01
Modality
AI / ML
AI PoS
42%
Strategic Deep Dive
Inhibition of the Calcium Channel ORAI1 as a Therapeutic Strategy for the Treatment of Oral Cancer and Associated Allodynia
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market2-4 yrs
PoS42%
Market TierTier 1
Use the device as a low-cost clinical workflow wedge, not a full therapeutic platform
Why this pivot works
Start with the narrowest procedure or diagnostic moment where the device changes a measurable decision: fewer repeat visits, faster detection, cleaner sampling, or reduced operator variability. Avoid building a broad hardware company until a paid workflow exists.
Capital discipline
Preserve cash by using off-the-shelf components, one KOL site, and a service-style pilot before tooling for scale.
Hurdles & Strategic Interventions
Primary BottleneckBlood-brain barrier penetration
AI Strategic InterventionUse delivery engineering, metabolic precursors, or peripheral surrogate endpoints.
Primary BottleneckClinical utility validation
AI Strategic InterventionPackage as a pharma enrichment tool before pursuing broad diagnostic reimbursement.
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeLicense option
Worth a short exclusive option if diligence confirms IP scope and inventor data quality.
Attractiveness Score72/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
72
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
84/100
Weight 10%Contribution 8 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
86/100
Weight 10%Contribution 9 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Use the device as a low-cost clinical workflow wedge, not a full therapeutic platform. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Retrospective validation plus one pharma pilot
Use banked samples or existing datasets to prove clinical utility before paying for a prospective study.
Phase 3Prospective enrichment study with IQVIA
Run the smallest study that proves the tool improves enrollment, stratification, or decision quality.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsCancera biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationCancer
Patients already represented in banked samples, trial datasets, or partner registries.
Study designRetrospective locked-dataset validation followed by one prospective pharma enrichment pilot.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Use the device as a low-cost clinical workflow wedge, not a full therapeutic platformRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stagebiomarker validation
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Use the device as a low-cost clinical workflow wedge, not a full therapeutic platform
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Peripheral or retinal surrogate strategy
Avoid a broad CNS endpoint first; prove mechanism through a measurable proxy.
Trial-enrichment service
Sell into pharma clinical operations before attempting broad reimbursement.
Final Recommendation
Proceed with repositioning
Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Use the device as a low-cost clinical workflow wedge, not a full therapeutic platform
Best next experiment
Run the smallest independent study that validates: Run a usability + analytical validation package first, then pursue a small prospective study at one high-volume clinical site.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Differentiated and precise approach for selectively targeting pain receptors to treat different types of pain effectively and safely without use of opioids.
NeurologySmall MoleculeBiologicAI / ML
Technology No.
BUN01-02
Modality
Small Molecule
AI PoS
24%
Strategic Deep Dive
Inhibitory Peptides That Selectively Antagonize Neuropilin 1 (NRP1) for Precise Pain Treatment
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-7 yrs
PoS24%
Market TierTier 2
Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Why this pivot works
Do not spend early capital proving a vague CNS efficacy story. First prove target engagement through a measurable rescue signal: CSF biomarker, retinal surrogate, peripheral immune marker, or metabolic precursor response that de-risks the brain hypothesis.
Capital discipline
Keep the first package biomarker-led and underpowered for efficacy; buy the right to run a real trial only after target engagement is visible.
Hurdles & Strategic Interventions
Primary BottleneckBlood-brain barrier penetration
AI Strategic InterventionUse delivery engineering, metabolic precursors, or peripheral surrogate endpoints.
Primary BottleneckClinical utility validation
AI Strategic InterventionPackage as a pharma enrichment tool before pursuing broad diagnostic reimbursement.
Buyer Map & IC Decision
Investment CommitteeLicense option
Worth a short exclusive option if diligence confirms IP scope and inventor data quality.
Attractiveness Score71/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Eli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
Biogen
CNS portfolio gap-filling and translational neurology focus.
Roche
CNS diagnostics, biomarkers, and global development scale.
Asset Attractiveness Score
71
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
80/100
Weight 15%Contribution 12 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Retrospective validation plus one pharma pilot
Use banked samples or existing datasets to prove clinical utility before paying for a prospective study.
Phase 3Prospective enrichment study with IQVIA
Run the smallest study that proves the tool improves enrollment, stratification, or decision quality.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Neurology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeEli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeBiogen
CNS portfolio gap-filling and translational neurology focus.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche
CNS diagnostics, biomarkers, and global development scale.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa biomarker-defined neuroinflammation or neurodegeneration subgroupa biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa biomarker-defined neuroinflammation or neurodegeneration subgroup
Patients already represented in banked samples, trial datasets, or partner registries.
Study designRetrospective locked-dataset validation followed by one prospective pharma enrichment pilot.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategyRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stagebiomarker validation
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Peripheral or retinal surrogate strategy
Avoid a broad CNS endpoint first; prove mechanism through a measurable proxy.
Trial-enrichment service
Sell into pharma clinical operations before attempting broad reimbursement.
Companion diagnostic option
Attach the technology to a partner drug where patient selection has immediate value.
Final Recommendation
Proceed with repositioning
Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Best next experiment
Run the smallest independent study that validates: Pair the asset with a brain-bioavailable precursor, nasal/local delivery, or exosome/nanoparticle carrier and gate spend on biomarker movement.
Best pharma targets
Eli Lilly, Biogen, Roche
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Injectable, minimally invasive, and effective disease-modifying therapeutic for post-traumatic osteoarthritis (PTOA) prevention and treatment
Inflammation
Technology No.
LIU02-02, MON02-04
Modality
Research platform
AI PoS
22%
Strategic Deep Dive
Injectable Therapeutic Hydrogel for the Treatment of Post-Traumatic Osteoarthritis
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Novartis
Broad modality appetite and academic-origin BD history.
Takeda
Translational science focus and partnership-friendly structure.
Sanofi
Immunology, rare disease, and platform-technology BD appetite.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Inflammation wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeNovartis
Broad modality appetite and academic-origin BD history.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeTakeda
Translational science focus and partnership-friendly structure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeSanofi
Immunology, rare disease, and platform-technology BD appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsthe narrowest patient segment where the mechanism can create a measurable signal quicklya biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationthe narrowest patient segment where the mechanism can create a measurable signal quickly
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Novartis, Takeda, Sanofi
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Disease-modifying therapy with differentiated mechanisms of action to restore memory and motor function in neurodegenerative diseases and neurodevelopmental disorders.
NeurologySmall Molecule
Technology No.
ALB01
Modality
Small Molecule
AI PoS
24%
Strategic Deep Dive
Innovative IGF-2 Receptor Agonists for Treating Neurodevelopmental Disorders and Neurodegenerative Diseases
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-7 yrs
PoS24%
Market TierTier 2
Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Why this pivot works
Do not spend early capital proving a vague CNS efficacy story. First prove target engagement through a measurable rescue signal: CSF biomarker, retinal surrogate, peripheral immune marker, or metabolic precursor response that de-risks the brain hypothesis.
Capital discipline
Keep the first package biomarker-led and underpowered for efficacy; buy the right to run a real trial only after target engagement is visible.
Hurdles & Strategic Interventions
Primary BottleneckBlood-brain barrier penetration
AI Strategic InterventionUse delivery engineering, metabolic precursors, or peripheral surrogate endpoints.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Eli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
Biogen
CNS portfolio gap-filling and translational neurology focus.
Roche
CNS diagnostics, biomarkers, and global development scale.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Neurology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeEli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeBiogen
CNS portfolio gap-filling and translational neurology focus.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche
CNS diagnostics, biomarkers, and global development scale.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa biomarker-defined neuroinflammation or neurodegeneration subgroupa biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa biomarker-defined neuroinflammation or neurodegeneration subgroup
Patients stratified by CSF, imaging, genetic, retinal, inflammatory, or metabolic markers.
Study designMechanism-first biomarker study before any broad symptomatic endpoint trial.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategyRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Peripheral or retinal surrogate strategy
Avoid a broad CNS endpoint first; prove mechanism through a measurable proxy.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Best next experiment
Run the smallest independent study that validates: Pair the asset with a brain-bioavailable precursor, nasal/local delivery, or exosome/nanoparticle carrier and gate spend on biomarker movement.
Best pharma targets
Eli Lilly, Biogen, Roche
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
A novel, innovative strategy for both treatment and prevention of HIV-1.
ImmunologyInfectious DiseaseBiologic
Technology No.
KON02-13
Modality
Biologic
AI PoS
30%
Strategic Deep Dive
Innovative Immune Complex Approach for Generating a Broadly Neutralizing Antibody Response to HIV-1
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market4-6 yrs
PoS30%
Market TierTier 2
Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Why this pivot works
Broad infectious-disease commercialization is brutal. The efficient path is a narrow, high-urgency segment where susceptibility, animal models, and compassionate-use logic can create a fast BD narrative.
Capital discipline
Spend first on microbiology proof and non-dilutive grant leverage; defer expensive GLP tox until the pathogen wedge is obvious.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
GSK
Vaccines and anti-infective infrastructure.
Pfizer
Hospital, anti-infective, and vaccine commercial reach.
Johnson & Johnson
Pathogen-focused development and global health channels.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Immunology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeGSK
Vaccines and anti-infective infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseePfizer
Hospital, anti-infective, and vaccine commercial reach.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeJohnson & Johnson
Pathogen-focused development and global health channels.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsHIVa biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationHIV
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launchRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Best next experiment
Run the smallest independent study that validates: Run pathogen-panel susceptibility, resistance mapping, and one translational model before any broad tox spend.
Best pharma targets
GSK, Pfizer, Johnson & Johnson
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Method of Treating Lung Cancer in Patients with LKB1 Genetically-Inactivated Tumors
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
Hurdles & Strategic Interventions
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsLung cancera biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationLung cancer
Molecularly defined patients with target expression, immune context, or resistance biology.
Study designBiomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Characterization of novel mechanisms driving cachexia and associated therapeutic targets for lung-cancer patients.
Oncology
Technology No.
PAP02-14
Modality
Research platform
AI PoS
22%
Strategic Deep Dive
Methods for Preventing Cancer Cachexia in Aggressive Lung Cancers
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
Hurdles & Strategic Interventions
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsLung cancera biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationLung cancer
Molecularly defined patients with target expression, immune context, or resistance biology.
Study designBiomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Methods of Sensitizing Estrogen Receptor-Positive Breast Cancer to Endocrine Therapy
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
Hurdles & Strategic Interventions
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsCancera biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationCancer
Molecularly defined patients with target expression, immune context, or resistance biology.
Study designBiomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Modulating Neuron and Oligodendrocyte Survival by Targeting Astrocyte-Secreted Neurotoxic Lipids and Lipoproteins
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-7 yrs
PoS24%
Market TierTier 2
Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Why this pivot works
Do not spend early capital proving a vague CNS efficacy story. First prove target engagement through a measurable rescue signal: CSF biomarker, retinal surrogate, peripheral immune marker, or metabolic precursor response that de-risks the brain hypothesis.
Capital discipline
Keep the first package biomarker-led and underpowered for efficacy; buy the right to run a real trial only after target engagement is visible.
Hurdles & Strategic Interventions
Primary BottleneckBlood-brain barrier penetration
AI Strategic InterventionUse delivery engineering, metabolic precursors, or peripheral surrogate endpoints.
Primary BottleneckFormulation and biodistribution risk
AI Strategic InterventionMove to localized administration and validate exposure with a focused PK package.
Buyer Map & IC Decision
Investment CommitteeLicense option
Worth a short exclusive option if diligence confirms IP scope and inventor data quality.
Attractiveness Score71/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Eli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
Biogen
CNS portfolio gap-filling and translational neurology focus.
Roche
CNS diagnostics, biomarkers, and global development scale.
Asset Attractiveness Score
71
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
80/100
Weight 15%Contribution 12 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Neurology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeEli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeBiogen
CNS portfolio gap-filling and translational neurology focus.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche
CNS diagnostics, biomarkers, and global development scale.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa biomarker-defined neuroinflammation or neurodegeneration subgroupa biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa biomarker-defined neuroinflammation or neurodegeneration subgroup
Patients stratified by CSF, imaging, genetic, retinal, inflammatory, or metabolic markers.
Study designMechanism-first biomarker study before any broad symptomatic endpoint trial.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategyRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Peripheral or retinal surrogate strategy
Avoid a broad CNS endpoint first; prove mechanism through a measurable proxy.
New delivery route
Pair the delivery system with a known payload and prove exposure advantage in a local indication.
Final Recommendation
Proceed with repositioning
Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Best next experiment
Run the smallest independent study that validates: Pair the asset with a brain-bioavailable precursor, nasal/local delivery, or exosome/nanoparticle carrier and gate spend on biomarker movement.
Best pharma targets
Eli Lilly, Biogen, Roche
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Effective removal of pathological albumin-bound uremic toxins in Chronic Kidney Disease patients, which are not removed by standard hemodialysis.
Cardiometabolic
Technology No.
KON02-10
Modality
Research platform
AI PoS
22%
Strategic Deep Dive
Monoclonal Antibodies for Efficient Removal of Uremic Toxins in Chronic Kidney Disease Patients
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Novartis
Broad modality appetite and academic-origin BD history.
Takeda
Translational science focus and partnership-friendly structure.
Sanofi
Immunology, rare disease, and platform-technology BD appetite.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Cardiometabolic wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeNovartis
Broad modality appetite and academic-origin BD history.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeTakeda
Translational science focus and partnership-friendly structure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeSanofi
Immunology, rare disease, and platform-technology BD appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsKidney diseasea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationKidney disease
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Novartis, Takeda, Sanofi
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Tailorable multivalent therapeutic for targeting difficult protein-protein interaction (PPI) interfaces in the context of cancer and infectious diseases
OncologyInfectious DiseaseBiologicAI / ML
Technology No.
MON02-11
Modality
Biologic
AI PoS
30%
Strategic Deep Dive
Multivalent Assembled Proteins (MAPs): Therapeutics for Cancer and Infectious Diseases
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market4-6 yrs
PoS30%
Market TierTier 2
Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Why this pivot works
Broad infectious-disease commercialization is brutal. The efficient path is a narrow, high-urgency segment where susceptibility, animal models, and compassionate-use logic can create a fast BD narrative.
Capital discipline
Spend first on microbiology proof and non-dilutive grant leverage; defer expensive GLP tox until the pathogen wedge is obvious.
Hurdles & Strategic Interventions
Primary BottleneckClinical utility validation
AI Strategic InterventionPackage as a pharma enrichment tool before pursuing broad diagnostic reimbursement.
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeLicense option
Worth a short exclusive option if diligence confirms IP scope and inventor data quality.
Attractiveness Score71/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
71
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
80/100
Weight 15%Contribution 12 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Retrospective validation plus one pharma pilot
Use banked samples or existing datasets to prove clinical utility before paying for a prospective study.
Phase 3Prospective enrichment study with IQVIA
Run the smallest study that proves the tool improves enrollment, stratification, or decision quality.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsCancera biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationCancer
Patients already represented in banked samples, trial datasets, or partner registries.
Study designRetrospective locked-dataset validation followed by one prospective pharma enrichment pilot.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launchRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stagebiomarker validation
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Trial-enrichment service
Sell into pharma clinical operations before attempting broad reimbursement.
Companion diagnostic option
Attach the technology to a partner drug where patient selection has immediate value.
Final Recommendation
Proceed with repositioning
Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Best next experiment
Run the smallest independent study that validates: Run pathogen-panel susceptibility, resistance mapping, and one translational model before any broad tox spend.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
A new generation of therapeutics for treating patients with enzalutamide-resistant CRPC.
Oncology
Technology No.
KIR01-10
Modality
Research platform
AI PoS
22%
Strategic Deep Dive
Multivalent Steroid Conjugates for Treatment of Castration-Resistant Prostate Cancer (CRPC)
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
Hurdles & Strategic Interventions
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsCancera biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationCancer
Molecularly defined patients with target expression, immune context, or resistance biology.
Study designBiomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Selective, differentiated, and efficacious antibody-based treatment for mutant HER2-mediated cancers without HER2 overexpression.
OncologyImmunologyBiologic
Technology No.
KOI01-08
Modality
Biologic
AI PoS
22%
Strategic Deep Dive
Mutant-Selective HER2 Antibodies for Treatment of Major Cancer Types
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
Hurdles & Strategic Interventions
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsCancera biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationCancer
Molecularly defined patients with target expression, immune context, or resistance biology.
Study designBiomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Innovative and efficacious therapeutic to treat current and future pan-coronavirus infections
Infectious DiseaseSmall Molecule
Technology No.
PAG01-15
Modality
Small Molecule
AI PoS
30%
Strategic Deep Dive
NSP14/10 Complex Inhibitors for the Treatment of SARS-CoV-2 and Pan-Coronavirus Infections
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market4-6 yrs
PoS30%
Market TierTier 2
Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Why this pivot works
Broad infectious-disease commercialization is brutal. The efficient path is a narrow, high-urgency segment where susceptibility, animal models, and compassionate-use logic can create a fast BD narrative.
Capital discipline
Spend first on microbiology proof and non-dilutive grant leverage; defer expensive GLP tox until the pathogen wedge is obvious.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
GSK
Vaccines and anti-infective infrastructure.
Pfizer
Hospital, anti-infective, and vaccine commercial reach.
Johnson & Johnson
Pathogen-focused development and global health channels.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Infectious Disease wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeGSK
Vaccines and anti-infective infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseePfizer
Hospital, anti-infective, and vaccine commercial reach.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeJohnson & Johnson
Pathogen-focused development and global health channels.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa resistant-pathogen niche with high unmet need and grant leveragea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa resistant-pathogen niche with high unmet need and grant leverage
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launchRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Best next experiment
Run the smallest independent study that validates: Run pathogen-panel susceptibility, resistance mapping, and one translational model before any broad tox spend.
Best pharma targets
GSK, Pfizer, Johnson & Johnson
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
A novel and cost-effective inorganic antibacterial composition.
Infectious Disease
Technology No.
ANI01-01
Modality
Research platform
AI PoS
30%
Strategic Deep Dive
Nano Zeolite-Y: A Novel and Cost-Effective Antibacterial Composition
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market4-6 yrs
PoS30%
Market TierTier 2
Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Why this pivot works
Broad infectious-disease commercialization is brutal. The efficient path is a narrow, high-urgency segment where susceptibility, animal models, and compassionate-use logic can create a fast BD narrative.
Capital discipline
Spend first on microbiology proof and non-dilutive grant leverage; defer expensive GLP tox until the pathogen wedge is obvious.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
GSK
Vaccines and anti-infective infrastructure.
Pfizer
Hospital, anti-infective, and vaccine commercial reach.
Johnson & Johnson
Pathogen-focused development and global health channels.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Infectious Disease wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeGSK
Vaccines and anti-infective infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseePfizer
Hospital, anti-infective, and vaccine commercial reach.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeJohnson & Johnson
Pathogen-focused development and global health channels.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa resistant-pathogen niche with high unmet need and grant leveragea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa resistant-pathogen niche with high unmet need and grant leverage
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launchRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Best next experiment
Run the smallest independent study that validates: Run pathogen-panel susceptibility, resistance mapping, and one translational model before any broad tox spend.
Best pharma targets
GSK, Pfizer, Johnson & Johnson
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Nanobodies Targeting SARS-CoV-2 NSP9 for COVID Treatment
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market4-6 yrs
PoS30%
Market TierTier 2
Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Why this pivot works
Broad infectious-disease commercialization is brutal. The efficient path is a narrow, high-urgency segment where susceptibility, animal models, and compassionate-use logic can create a fast BD narrative.
Capital discipline
Spend first on microbiology proof and non-dilutive grant leverage; defer expensive GLP tox until the pathogen wedge is obvious.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
GSK
Vaccines and anti-infective infrastructure.
Pfizer
Hospital, anti-infective, and vaccine commercial reach.
Johnson & Johnson
Pathogen-focused development and global health channels.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Infectious Disease wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeGSK
Vaccines and anti-infective infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseePfizer
Hospital, anti-infective, and vaccine commercial reach.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeJohnson & Johnson
Pathogen-focused development and global health channels.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsCOVID-19a biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationCOVID-19
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launchRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Best next experiment
Run the smallest independent study that validates: Run pathogen-panel susceptibility, resistance mapping, and one translational model before any broad tox spend.
Best pharma targets
GSK, Pfizer, Johnson & Johnson
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Precise and preventive therapeutic strategy for patients with a high risk of developing colorectal cancer.
OncologySmall MoleculeAI / ML
Technology No.
HEA01-01
Modality
Small Molecule
AI PoS
45%
Strategic Deep Dive
Natural & Semi-Synthetic Prodrugs as Selective Antibiotics Against Colibactin-Producing E. coli for Colorectal Cancer Prevention
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market2-4 yrs
PoS45%
Market TierTier 1
Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Why this pivot works
Reimbursement can wait. The cash-efficient path is to sell the technology as a trial-enrichment, patient-stratification, or translational biomarker service to pharma teams that already have trial budgets.
Capital discipline
Use fee-for-service pilots to fund validation; avoid building a regulated diagnostic company before buyer pull is proven.
Hurdles & Strategic Interventions
Primary BottleneckClinical utility validation
AI Strategic InterventionPackage as a pharma enrichment tool before pursuing broad diagnostic reimbursement.
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteePartner outreach
Strong enough to test buyer appetite now while validating the cheapest decisive experiment.
Attractiveness Score74/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
74
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
80/100
Weight 15%Contribution 12 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
84/100
Weight 10%Contribution 8 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
86/100
Weight 10%Contribution 9 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Retrospective validation plus one pharma pilot
Use banked samples or existing datasets to prove clinical utility before paying for a prospective study.
Phase 3Prospective enrichment study with IQVIA
Run the smallest study that proves the tool improves enrollment, stratification, or decision quality.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsCancera biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationCancer
Patients already represented in banked samples, trial datasets, or partner registries.
Study designRetrospective locked-dataset validation followed by one prospective pharma enrichment pilot.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Monetize first as a pharma enrichment engine, not a reimbursed diagnosticRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stagebiomarker validation
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Trial-enrichment service
Sell into pharma clinical operations before attempting broad reimbursement.
Companion diagnostic option
Attach the technology to a partner drug where patient selection has immediate value.
Final Recommendation
Proceed
Strong enough to test buyer appetite now while validating the cheapest decisive experiment. The most investable version is: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Best next experiment
Run the smallest independent study that validates: Package the model or assay with a locked validation dataset, CLIA/service workflow, and one sponsor-ready use case.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Innovative and effective therapies for treating Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic SteatoHepatitis (NASH)
Cardiometabolic
Technology No.
MOO02-06
Modality
Research platform
AI PoS
22%
Strategic Deep Dive
Netrin-1 and UNC5B as Novel Targets in Metabolic Liver Diseases: NAFLD & NASH
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Novartis
Broad modality appetite and academic-origin BD history.
Takeda
Translational science focus and partnership-friendly structure.
Sanofi
Immunology, rare disease, and platform-technology BD appetite.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Cardiometabolic wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeNovartis
Broad modality appetite and academic-origin BD history.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeTakeda
Translational science focus and partnership-friendly structure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeSanofi
Immunology, rare disease, and platform-technology BD appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsLiver diseasea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationLiver disease
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Novartis, Takeda, Sanofi
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
A cost-effective, sustainable, and customizable alternative to primary amniotic membranes for wound healing and regeneration.
AI / ML
Technology No.
BRA08-01
Modality
AI / ML
AI PoS
45%
Strategic Deep Dive
Next-Generation Regenerative Therapy for Wound Healing
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market2-4 yrs
PoS45%
Market TierTier 1
Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Why this pivot works
Reimbursement can wait. The cash-efficient path is to sell the technology as a trial-enrichment, patient-stratification, or translational biomarker service to pharma teams that already have trial budgets.
Capital discipline
Use fee-for-service pilots to fund validation; avoid building a regulated diagnostic company before buyer pull is proven.
Hurdles & Strategic Interventions
Primary BottleneckClinical utility validation
AI Strategic InterventionPackage as a pharma enrichment tool before pursuing broad diagnostic reimbursement.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Roche Diagnostics
Companion diagnostic and translational biomarker fit.
Thermo Fisher
Research-tool commercialization and pharma services channels.
Illumina / Tempus
Data, sequencing, and clinical decision-support adjacency.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
62/100
Weight 15%Contribution 9 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
84/100
Weight 10%Contribution 8 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
86/100
Weight 10%Contribution 9 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Retrospective validation plus one pharma pilot
Use banked samples or existing datasets to prove clinical utility before paying for a prospective study.
Phase 3Prospective enrichment study with IQVIA
Run the smallest study that proves the tool improves enrollment, stratification, or decision quality.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp specialty therapeutics wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeRoche Diagnostics
Companion diagnostic and translational biomarker fit.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeThermo Fisher
Research-tool commercialization and pharma services channels.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeIllumina / Tempus
Data, sequencing, and clinical decision-support adjacency.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa pharma trial-enrichment use case before broad diagnostic commercializationa biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa pharma trial-enrichment use case before broad diagnostic commercialization
Patients already represented in banked samples, trial datasets, or partner registries.
Study designRetrospective locked-dataset validation followed by one prospective pharma enrichment pilot.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Monetize first as a pharma enrichment engine, not a reimbursed diagnosticRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stagebiomarker validation
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Trial-enrichment service
Sell into pharma clinical operations before attempting broad reimbursement.
Companion diagnostic option
Attach the technology to a partner drug where patient selection has immediate value.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Best next experiment
Run the smallest independent study that validates: Package the model or assay with a locked validation dataset, CLIA/service workflow, and one sponsor-ready use case.
Best pharma targets
Roche Diagnostics, Thermo Fisher, Illumina / Tempus
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Using re-engineered genetic elements of bacteria as antibacterial drones to block bacterial genes involved in virulence/viability.
Infectious Disease
Technology No.
NOV01-14
Modality
Research platform
AI PoS
30%
Strategic Deep Dive
Non-Antibiotic Treatment of Staphylococcal Infections
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market4-6 yrs
PoS30%
Market TierTier 2
Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Why this pivot works
Broad infectious-disease commercialization is brutal. The efficient path is a narrow, high-urgency segment where susceptibility, animal models, and compassionate-use logic can create a fast BD narrative.
Capital discipline
Spend first on microbiology proof and non-dilutive grant leverage; defer expensive GLP tox until the pathogen wedge is obvious.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
GSK
Vaccines and anti-infective infrastructure.
Pfizer
Hospital, anti-infective, and vaccine commercial reach.
Johnson & Johnson
Pathogen-focused development and global health channels.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Infectious Disease wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeGSK
Vaccines and anti-infective infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseePfizer
Hospital, anti-infective, and vaccine commercial reach.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeJohnson & Johnson
Pathogen-focused development and global health channels.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa resistant-pathogen niche with high unmet need and grant leveragea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa resistant-pathogen niche with high unmet need and grant leverage
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launchRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Best next experiment
Run the smallest independent study that validates: Run pathogen-panel susceptibility, resistance mapping, and one translational model before any broad tox spend.
Best pharma targets
GSK, Pfizer, Johnson & Johnson
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
A new avenue for cancer immunotherapies and biologics.
OncologyBiologic
Technology No.
BAN03-02
Modality
Biologic
AI PoS
22%
Strategic Deep Dive
Non-Genetic Induction of Tumor Neoantigens via Translational Errors
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
Hurdles & Strategic Interventions
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsCancera biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationCancer
Molecularly defined patients with target expression, immune context, or resistance biology.
Study designBiomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Novel Biomarkers for Detection and Treatment of Immune Deficiencies During Pregnancy
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 3
AI-Optimized Strategy Track
Time to Market4-6 yrs
PoS30%
Market TierTier 2
Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Why this pivot works
Broad infectious-disease commercialization is brutal. The efficient path is a narrow, high-urgency segment where susceptibility, animal models, and compassionate-use logic can create a fast BD narrative.
Capital discipline
Spend first on microbiology proof and non-dilutive grant leverage; defer expensive GLP tox until the pathogen wedge is obvious.
Hurdles & Strategic Interventions
Primary BottleneckClinical utility validation
AI Strategic InterventionPackage as a pharma enrichment tool before pursuing broad diagnostic reimbursement.
Buyer Map & IC Decision
Investment CommitteeLicense option
Worth a short exclusive option if diligence confirms IP scope and inventor data quality.
Attractiveness Score71/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
GSK
Vaccines and anti-infective infrastructure.
Pfizer
Hospital, anti-infective, and vaccine commercial reach.
Johnson & Johnson
Pathogen-focused development and global health channels.
Asset Attractiveness Score
71
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
82/100
Weight 15%Contribution 12 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical Validation Partner
Medpace, Precision for Medicine, Q2 Solutions
Biomarker validation and sample logistics
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Retrospective validation plus one pharma pilot
Use banked samples or existing datasets to prove clinical utility before paying for a prospective study.
Phase 3Prospective enrichment study with Medpace
Run the smallest study that proves the tool improves enrollment, stratification, or decision quality.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Immunology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeGSK
Vaccines and anti-infective infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseePfizer
Hospital, anti-infective, and vaccine commercial reach.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeJohnson & Johnson
Pathogen-focused development and global health channels.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa resistant-pathogen niche with high unmet need and grant leveragea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa resistant-pathogen niche with high unmet need and grant leverage
Patients already represented in banked samples, trial datasets, or partner registries.
Study designRetrospective locked-dataset validation followed by one prospective pharma enrichment pilot.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launchRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stagebiomarker validation
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Trial-enrichment service
Sell into pharma clinical operations before attempting broad reimbursement.
Companion diagnostic option
Attach the technology to a partner drug where patient selection has immediate value.
Final Recommendation
Proceed with repositioning
Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Best next experiment
Run the smallest independent study that validates: Run pathogen-panel susceptibility, resistance mapping, and one translational model before any broad tox spend.
Best pharma targets
GSK, Pfizer, Johnson & Johnson
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Novel Biomarkers for Platelet Reactivity and Cardiovascular Risk: “PRESS” and “PROSPER”
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 3
AI-Optimized Strategy Track
Time to Market2-4 yrs
PoS45%
Market TierTier 1
Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Why this pivot works
Reimbursement can wait. The cash-efficient path is to sell the technology as a trial-enrichment, patient-stratification, or translational biomarker service to pharma teams that already have trial budgets.
Capital discipline
Use fee-for-service pilots to fund validation; avoid building a regulated diagnostic company before buyer pull is proven.
Hurdles & Strategic Interventions
Primary BottleneckClinical utility validation
AI Strategic InterventionPackage as a pharma enrichment tool before pursuing broad diagnostic reimbursement.
Buyer Map & IC Decision
Investment CommitteePartner outreach
Strong enough to test buyer appetite now while validating the cheapest decisive experiment.
Attractiveness Score76/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Roche Diagnostics
Companion diagnostic and translational biomarker fit.
Thermo Fisher
Research-tool commercialization and pharma services channels.
Illumina / Tempus
Data, sequencing, and clinical decision-support adjacency.
Asset Attractiveness Score
76
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
82/100
Weight 15%Contribution 12 pts
Differentiation
How clearly the technology can be positioned as different.
80/100
Weight 15%Contribution 12 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
84/100
Weight 10%Contribution 8 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
86/100
Weight 10%Contribution 9 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical Validation Partner
Medpace, Precision for Medicine, Q2 Solutions
Biomarker validation and sample logistics
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Retrospective validation plus one pharma pilot
Use banked samples or existing datasets to prove clinical utility before paying for a prospective study.
Phase 3Prospective enrichment study with Medpace
Run the smallest study that proves the tool improves enrollment, stratification, or decision quality.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Cardiometabolic wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeRoche Diagnostics
Companion diagnostic and translational biomarker fit.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeThermo Fisher
Research-tool commercialization and pharma services channels.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeIllumina / Tempus
Data, sequencing, and clinical decision-support adjacency.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa pharma trial-enrichment use case before broad diagnostic commercializationa biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa pharma trial-enrichment use case before broad diagnostic commercialization
Patients already represented in banked samples, trial datasets, or partner registries.
Study designRetrospective locked-dataset validation followed by one prospective pharma enrichment pilot.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Monetize first as a pharma enrichment engine, not a reimbursed diagnosticRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stagebiomarker validation
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Trial-enrichment service
Sell into pharma clinical operations before attempting broad reimbursement.
Companion diagnostic option
Attach the technology to a partner drug where patient selection has immediate value.
Final Recommendation
Proceed
Strong enough to test buyer appetite now while validating the cheapest decisive experiment. The most investable version is: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Best next experiment
Run the smallest independent study that validates: Package the model or assay with a locked validation dataset, CLIA/service workflow, and one sponsor-ready use case.
Best pharma targets
Roche Diagnostics, Thermo Fisher, Illumina / Tempus
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Novel anthelmintics with differentiated mechanisms of actions and therapeutic efficacy across multiple developmental stages
Small Molecule
Technology No.
PIA01-02
Modality
Small Molecule
AI PoS
22%
Strategic Deep Dive
Novel Class of Anthelmintic Compounds and Proprietary Screening Method for Anthelmintic Discovery
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 3
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score66/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Roche Diagnostics
Companion diagnostic and translational biomarker fit.
Thermo Fisher
Research-tool commercialization and pharma services channels.
Illumina / Tempus
Data, sequencing, and clinical decision-support adjacency.
Asset Attractiveness Score
66
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
62/100
Weight 15%Contribution 9 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical Validation Partner
Medpace, Precision for Medicine, Q2 Solutions
Biomarker validation and sample logistics
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with Medpace
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp specialty therapeutics wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeRoche Diagnostics
Companion diagnostic and translational biomarker fit.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeThermo Fisher
Research-tool commercialization and pharma services channels.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeIllumina / Tempus
Data, sequencing, and clinical decision-support adjacency.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsthe narrowest patient segment where the mechanism can create a measurable signal quicklya biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationthe narrowest patient segment where the mechanism can create a measurable signal quickly
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Roche Diagnostics, Thermo Fisher, Illumina / Tempus
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
An efficient approach to treat a large subset of patients with non-small cell lung carcinoma who don’t respond to conventional immune therapy.
OncologyImmunology
Technology No.
PAP02-04
Modality
Cell engineering platform
AI PoS
22%
Strategic Deep Dive
Novel Immune Based Therapeutic Strategies to Target Tumors with Alterations in LKB1 Pathway
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
Hurdles & Strategic Interventions
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa molecularly selected tumor segment where a small proof-of-mechanism study is crediblea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa molecularly selected tumor segment where a small proof-of-mechanism study is credible
Molecularly defined patients with target expression, immune context, or resistance biology.
Study designBiomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Novel peptides for treating conditions or diseases resulting from dysregulation in the immune system, such as septic shock, wound healing and autoimmune diseases.
ImmunologyInflammationBiologic
Technology No.
CHA10-02
Modality
Biologic
AI PoS
22%
Strategic Deep Dive
Novel Lumican-Binding Peptides Acting on the Toll-Like Receptor Pathway in Inflammation and Related Conditions
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Novartis
Broad modality appetite and academic-origin BD history.
Takeda
Translational science focus and partnership-friendly structure.
Sanofi
Immunology, rare disease, and platform-technology BD appetite.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Immunology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeNovartis
Broad modality appetite and academic-origin BD history.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeTakeda
Translational science focus and partnership-friendly structure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeSanofi
Immunology, rare disease, and platform-technology BD appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsAutoimmune diseasea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationAutoimmune disease
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Novartis, Takeda, Sanofi
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Novel MicroRNA-30c Analogs to Reduce Secretion of Apolipoprotein B in Human Hepatoma Cells
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market5-6 yrs
PoS28%
Market TierTier 2
Turn delivery into the asset by choosing a toxicity-sensitive local indication
Why this pivot works
A delivery technology wins when it solves a painful tradeoff: high local exposure with low systemic burden. Pick an indication where reduced dose, fewer adverse events, or easier administration is the buyer's actual reason to care.
Capital discipline
Use a validated payload and small PK package; do not fund broad platform claims until one local-use case works.
Hurdles & Strategic Interventions
Primary BottleneckFormulation and biodistribution risk
AI Strategic InterventionMove to localized administration and validate exposure with a focused PK package.
Buyer Map & IC Decision
Investment CommitteeLicense option
Worth a short exclusive option if diligence confirms IP scope and inventor data quality.
Attractiveness Score71/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Novartis
Broad modality appetite and academic-origin BD history.
Takeda
Translational science focus and partnership-friendly structure.
Sanofi
Immunology, rare disease, and platform-technology BD appetite.
Asset Attractiveness Score
71
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
80/100
Weight 15%Contribution 12 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Turn delivery into the asset by choosing a toxicity-sensitive local indication. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Cardiometabolic wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeNovartis
Broad modality appetite and academic-origin BD history.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeTakeda
Translational science focus and partnership-friendly structure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeSanofi
Immunology, rare disease, and platform-technology BD appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsthe narrowest patient segment where the mechanism can create a measurable signal quicklya biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationthe narrowest patient segment where the mechanism can create a measurable signal quickly
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Turn delivery into the asset by choosing a toxicity-sensitive local indicationRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Turn delivery into the asset by choosing a toxicity-sensitive local indication
New delivery route
Pair the delivery system with a known payload and prove exposure advantage in a local indication.
Final Recommendation
Proceed with repositioning
Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Turn delivery into the asset by choosing a toxicity-sensitive local indication
Best next experiment
Run the smallest independent study that validates: Run biodistribution and local tolerability first, then attach the platform to a known active payload instead of inventing a new drug story.
Best pharma targets
Novartis, Takeda, Sanofi
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Innovative probiotic formulation to prevent and treat metabolic and immune disorders
ImmunologyCardiometabolic
Technology No.
BLA02-12
Modality
Research platform
AI PoS
22%
Strategic Deep Dive
Novel Probiotic Compositions for Improving Metabolism and Immunity
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Novartis
Broad modality appetite and academic-origin BD history.
Takeda
Translational science focus and partnership-friendly structure.
Sanofi
Immunology, rare disease, and platform-technology BD appetite.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Immunology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeNovartis
Broad modality appetite and academic-origin BD history.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeTakeda
Translational science focus and partnership-friendly structure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeSanofi
Immunology, rare disease, and platform-technology BD appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsthe narrowest patient segment where the mechanism can create a measurable signal quicklya biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationthe narrowest patient segment where the mechanism can create a measurable signal quickly
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Novartis, Takeda, Sanofi
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Aft7ip and Setdb1 identified as novel anti-cancer therapeutic targets
Oncology
Technology No.
WON02-04
Modality
Research platform
AI PoS
22%
Strategic Deep Dive
Novel Targets for Cancer Therapy
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
Hurdles & Strategic Interventions
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsCancera biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationCancer
Molecularly defined patients with target expression, immune context, or resistance biology.
Study designBiomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Novel miRNA and Protein Therapeutic Targets to Reduce Atherosclerosis
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score66/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Novartis
Broad modality appetite and academic-origin BD history.
Takeda
Translational science focus and partnership-friendly structure.
Sanofi
Immunology, rare disease, and platform-technology BD appetite.
Asset Attractiveness Score
66
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
62/100
Weight 15%Contribution 9 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp specialty therapeutics wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeNovartis
Broad modality appetite and academic-origin BD history.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeTakeda
Translational science focus and partnership-friendly structure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeSanofi
Immunology, rare disease, and platform-technology BD appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsthe narrowest patient segment where the mechanism can create a measurable signal quicklya biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationthe narrowest patient segment where the mechanism can create a measurable signal quickly
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Novartis, Takeda, Sanofi
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Osteoarthritis (OA) Biomarker Suitable as a Point-of-Care Diagnostic
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 3
AI-Optimized Strategy Track
Time to Market2-4 yrs
PoS45%
Market TierTier 1
Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Why this pivot works
Reimbursement can wait. The cash-efficient path is to sell the technology as a trial-enrichment, patient-stratification, or translational biomarker service to pharma teams that already have trial budgets.
Capital discipline
Use fee-for-service pilots to fund validation; avoid building a regulated diagnostic company before buyer pull is proven.
Hurdles & Strategic Interventions
Primary BottleneckClinical utility validation
AI Strategic InterventionPackage as a pharma enrichment tool before pursuing broad diagnostic reimbursement.
Buyer Map & IC Decision
Investment CommitteePartner outreach
Strong enough to test buyer appetite now while validating the cheapest decisive experiment.
Attractiveness Score74/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Roche Diagnostics
Companion diagnostic and translational biomarker fit.
Thermo Fisher
Research-tool commercialization and pharma services channels.
Illumina / Tempus
Data, sequencing, and clinical decision-support adjacency.
Asset Attractiveness Score
74
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
82/100
Weight 15%Contribution 12 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
84/100
Weight 10%Contribution 8 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
86/100
Weight 10%Contribution 9 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical Validation Partner
Medpace, Precision for Medicine, Q2 Solutions
Biomarker validation and sample logistics
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Retrospective validation plus one pharma pilot
Use banked samples or existing datasets to prove clinical utility before paying for a prospective study.
Phase 3Prospective enrichment study with Medpace
Run the smallest study that proves the tool improves enrollment, stratification, or decision quality.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Inflammation wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeRoche Diagnostics
Companion diagnostic and translational biomarker fit.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeThermo Fisher
Research-tool commercialization and pharma services channels.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeIllumina / Tempus
Data, sequencing, and clinical decision-support adjacency.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa pharma trial-enrichment use case before broad diagnostic commercializationa biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa pharma trial-enrichment use case before broad diagnostic commercialization
Patients already represented in banked samples, trial datasets, or partner registries.
Study designRetrospective locked-dataset validation followed by one prospective pharma enrichment pilot.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Monetize first as a pharma enrichment engine, not a reimbursed diagnosticRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stagebiomarker validation
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Trial-enrichment service
Sell into pharma clinical operations before attempting broad reimbursement.
Companion diagnostic option
Attach the technology to a partner drug where patient selection has immediate value.
Final Recommendation
Proceed
Strong enough to test buyer appetite now while validating the cheapest decisive experiment. The most investable version is: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Best next experiment
Run the smallest independent study that validates: Package the model or assay with a locked validation dataset, CLIA/service workflow, and one sponsor-ready use case.
Best pharma targets
Roche Diagnostics, Thermo Fisher, Illumina / Tempus
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Easy-to-use, inexpensive, accurate, and customizable pathogen detection devices.
Infectious DiseaseDiagnostic / Biomarker
Technology No.
QAS01-09
Modality
Diagnostic / Biomarker
AI PoS
42%
Strategic Deep Dive
Paper-Based, Multiplexed Lamp Diagnostic for Pathogen Detection
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market2-4 yrs
PoS42%
Market TierTier 1
Use the device as a low-cost clinical workflow wedge, not a full therapeutic platform
Why this pivot works
Start with the narrowest procedure or diagnostic moment where the device changes a measurable decision: fewer repeat visits, faster detection, cleaner sampling, or reduced operator variability. Avoid building a broad hardware company until a paid workflow exists.
Capital discipline
Preserve cash by using off-the-shelf components, one KOL site, and a service-style pilot before tooling for scale.
Hurdles & Strategic Interventions
Primary BottleneckClinical utility validation
AI Strategic InterventionPackage as a pharma enrichment tool before pursuing broad diagnostic reimbursement.
Buyer Map & IC Decision
Investment CommitteePartner outreach
Strong enough to test buyer appetite now while validating the cheapest decisive experiment.
Attractiveness Score74/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
GSK
Vaccines and anti-infective infrastructure.
Pfizer
Hospital, anti-infective, and vaccine commercial reach.
Johnson & Johnson
Pathogen-focused development and global health channels.
Asset Attractiveness Score
74
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
82/100
Weight 15%Contribution 12 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
84/100
Weight 10%Contribution 8 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
86/100
Weight 10%Contribution 9 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical Validation Partner
Medpace, Precision for Medicine, Q2 Solutions
Biomarker validation and sample logistics
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Use the device as a low-cost clinical workflow wedge, not a full therapeutic platform. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Retrospective validation plus one pharma pilot
Use banked samples or existing datasets to prove clinical utility before paying for a prospective study.
Phase 3Prospective enrichment study with Medpace
Run the smallest study that proves the tool improves enrollment, stratification, or decision quality.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Infectious Disease wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeGSK
Vaccines and anti-infective infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseePfizer
Hospital, anti-infective, and vaccine commercial reach.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeJohnson & Johnson
Pathogen-focused development and global health channels.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa resistant-pathogen niche with high unmet need and grant leveragea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa resistant-pathogen niche with high unmet need and grant leverage
Patients already represented in banked samples, trial datasets, or partner registries.
Study designRetrospective locked-dataset validation followed by one prospective pharma enrichment pilot.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Use the device as a low-cost clinical workflow wedge, not a full therapeutic platformRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stagebiomarker validation
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Use the device as a low-cost clinical workflow wedge, not a full therapeutic platform
Trial-enrichment service
Sell into pharma clinical operations before attempting broad reimbursement.
Companion diagnostic option
Attach the technology to a partner drug where patient selection has immediate value.
Final Recommendation
Proceed
Strong enough to test buyer appetite now while validating the cheapest decisive experiment. The most investable version is: Use the device as a low-cost clinical workflow wedge, not a full therapeutic platform
Best next experiment
Run the smallest independent study that validates: Run a usability + analytical validation package first, then pursue a small prospective study at one high-volume clinical site.
Best pharma targets
GSK, Pfizer, Johnson & Johnson
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Effective and non-addictive chronic pain therapeutics with minimal side effects.
NeurologyAI / ML
Technology No.
KHA03-01
Modality
AI / ML
AI PoS
24%
Strategic Deep Dive
Peptidomimetic Modulator of CaV2.2 N-type Calcium Channel for Treatment of Chronic Pain
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-7 yrs
PoS24%
Market TierTier 2
Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Why this pivot works
Do not spend early capital proving a vague CNS efficacy story. First prove target engagement through a measurable rescue signal: CSF biomarker, retinal surrogate, peripheral immune marker, or metabolic precursor response that de-risks the brain hypothesis.
Capital discipline
Keep the first package biomarker-led and underpowered for efficacy; buy the right to run a real trial only after target engagement is visible.
Hurdles & Strategic Interventions
Primary BottleneckBlood-brain barrier penetration
AI Strategic InterventionUse delivery engineering, metabolic precursors, or peripheral surrogate endpoints.
Primary BottleneckClinical utility validation
AI Strategic InterventionPackage as a pharma enrichment tool before pursuing broad diagnostic reimbursement.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Eli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
Biogen
CNS portfolio gap-filling and translational neurology focus.
Roche
CNS diagnostics, biomarkers, and global development scale.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Retrospective validation plus one pharma pilot
Use banked samples or existing datasets to prove clinical utility before paying for a prospective study.
Phase 3Prospective enrichment study with IQVIA
Run the smallest study that proves the tool improves enrollment, stratification, or decision quality.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Neurology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeEli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeBiogen
CNS portfolio gap-filling and translational neurology focus.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche
CNS diagnostics, biomarkers, and global development scale.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa biomarker-defined neuroinflammation or neurodegeneration subgroupa biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa biomarker-defined neuroinflammation or neurodegeneration subgroup
Patients already represented in banked samples, trial datasets, or partner registries.
Study designRetrospective locked-dataset validation followed by one prospective pharma enrichment pilot.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategyRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stagebiomarker validation
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Peripheral or retinal surrogate strategy
Avoid a broad CNS endpoint first; prove mechanism through a measurable proxy.
Trial-enrichment service
Sell into pharma clinical operations before attempting broad reimbursement.
Companion diagnostic option
Attach the technology to a partner drug where patient selection has immediate value.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Best next experiment
Run the smallest independent study that validates: Pair the asset with a brain-bioavailable precursor, nasal/local delivery, or exosome/nanoparticle carrier and gate spend on biomarker movement.
Best pharma targets
Eli Lilly, Biogen, Roche
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
A novel and innovative organoid co-culture system for studying immune-mediated tissue damage and testing patient responses to therapies for inflammatory disorders.
ImmunologyInflammationBiomanufacturing
Technology No.
CAD01-04
Modality
Biomanufacturing
AI PoS
22%
Strategic Deep Dive
Personalized Ex Vivo Platform for Testing Patient Responsiveness to Therapeutics for Inflammatory Disorders
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 3
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Roche Diagnostics
Companion diagnostic and translational biomarker fit.
Thermo Fisher
Research-tool commercialization and pharma services channels.
Illumina / Tempus
Data, sequencing, and clinical decision-support adjacency.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical Validation Partner
Medpace, Precision for Medicine, Q2 Solutions
Biomarker validation and sample logistics
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with Medpace
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Immunology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeRoche Diagnostics
Companion diagnostic and translational biomarker fit.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeThermo Fisher
Research-tool commercialization and pharma services channels.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeIllumina / Tempus
Data, sequencing, and clinical decision-support adjacency.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsInflammatory diseasea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationInflammatory disease
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Roche Diagnostics, Thermo Fisher, Illumina / Tempus
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Next-generation ADC platforms with high specificity and reduced systemic toxicity
ImmunologySmall MoleculeBiologic
Technology No.
NEE02-08
Modality
Small Molecule
AI PoS
22%
Strategic Deep Dive
Platform for Locally Assembling Antibody Drug Conjugates (ADCs) With Enhanced Specificity
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 3
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeLicense option
Worth a short exclusive option if diligence confirms IP scope and inventor data quality.
Attractiveness Score71/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Roche Diagnostics
Companion diagnostic and translational biomarker fit.
Thermo Fisher
Research-tool commercialization and pharma services channels.
Illumina / Tempus
Data, sequencing, and clinical decision-support adjacency.
Asset Attractiveness Score
71
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
80/100
Weight 15%Contribution 12 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical Validation Partner
Medpace, Precision for Medicine, Q2 Solutions
Biomarker validation and sample logistics
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with Medpace
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Immunology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeRoche Diagnostics
Companion diagnostic and translational biomarker fit.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeThermo Fisher
Research-tool commercialization and pharma services channels.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeIllumina / Tempus
Data, sequencing, and clinical decision-support adjacency.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsthe narrowest patient segment where the mechanism can create a measurable signal quicklya biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationthe narrowest patient segment where the mechanism can create a measurable signal quickly
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Roche Diagnostics, Thermo Fisher, Illumina / Tempus
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
A lung-targeted, resistance-proof prophylactic that prevents inflammatory lung injury from respiratory viral infections without systemic immunosuppression and pathogen clearance.
InflammationInfectious Disease
Technology No.
KHA02-03
Modality
Research platform
AI PoS
30%
Strategic Deep Dive
Prophylactic Strategy to Prevent Inflammatory Lung Injury from Diverse Respiratory Viruses via NAM Reprogramming
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market4-6 yrs
PoS30%
Market TierTier 2
Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Why this pivot works
Broad infectious-disease commercialization is brutal. The efficient path is a narrow, high-urgency segment where susceptibility, animal models, and compassionate-use logic can create a fast BD narrative.
Capital discipline
Spend first on microbiology proof and non-dilutive grant leverage; defer expensive GLP tox until the pathogen wedge is obvious.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
GSK
Vaccines and anti-infective infrastructure.
Pfizer
Hospital, anti-infective, and vaccine commercial reach.
Johnson & Johnson
Pathogen-focused development and global health channels.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Inflammation wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeGSK
Vaccines and anti-infective infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseePfizer
Hospital, anti-infective, and vaccine commercial reach.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeJohnson & Johnson
Pathogen-focused development and global health channels.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsInflammatory diseasea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationInflammatory disease
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launchRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Best next experiment
Run the smallest independent study that validates: Run pathogen-panel susceptibility, resistance mapping, and one translational model before any broad tox spend.
Best pharma targets
GSK, Pfizer, Johnson & Johnson
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Innovative approach to correct C9ORF72 Loss-of-Function and restore protein levels in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD).
NeurologyBiologic
Technology No.
VOG01-02
Modality
Biologic
AI PoS
24%
Strategic Deep Dive
RNA-Editing of C9ORF72 Loss-of-Function for Treatment of Neurodegenerative Diseases
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-7 yrs
PoS24%
Market TierTier 2
Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Why this pivot works
Do not spend early capital proving a vague CNS efficacy story. First prove target engagement through a measurable rescue signal: CSF biomarker, retinal surrogate, peripheral immune marker, or metabolic precursor response that de-risks the brain hypothesis.
Capital discipline
Keep the first package biomarker-led and underpowered for efficacy; buy the right to run a real trial only after target engagement is visible.
Hurdles & Strategic Interventions
Primary BottleneckBlood-brain barrier penetration
AI Strategic InterventionUse delivery engineering, metabolic precursors, or peripheral surrogate endpoints.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Eli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
Biogen
CNS portfolio gap-filling and translational neurology focus.
Roche
CNS diagnostics, biomarkers, and global development scale.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Neurology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeEli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeBiogen
CNS portfolio gap-filling and translational neurology focus.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche
CNS diagnostics, biomarkers, and global development scale.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa biomarker-defined neuroinflammation or neurodegeneration subgroupa biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa biomarker-defined neuroinflammation or neurodegeneration subgroup
Patients stratified by CSF, imaging, genetic, retinal, inflammatory, or metabolic markers.
Study designMechanism-first biomarker study before any broad symptomatic endpoint trial.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategyRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Peripheral or retinal surrogate strategy
Avoid a broad CNS endpoint first; prove mechanism through a measurable proxy.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Best next experiment
Run the smallest independent study that validates: Pair the asset with a brain-bioavailable precursor, nasal/local delivery, or exosome/nanoparticle carrier and gate spend on biomarker movement.
Best pharma targets
Eli Lilly, Biogen, Roche
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Effective strategies to reprogram immunosuppressive tumor-associated macrophages (TAMs) and overcome resistance to current immunotherapies.
Oncology
Technology No.
KHA02-02
Modality
Research platform
AI PoS
22%
Strategic Deep Dive
Reprogramming Lung Tumor Immunity by Inhibiting C1Q on Tumor-Associated Macrophages (TAMs)
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
Hurdles & Strategic Interventions
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa molecularly selected tumor segment where a small proof-of-mechanism study is crediblea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa molecularly selected tumor segment where a small proof-of-mechanism study is credible
Molecularly defined patients with target expression, immune context, or resistance biology.
Study designBiomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
First-in-class treatment of cerebral malaria by preventing the pathological loss of the blood-brain barrier.
NeurologyInfectious DiseaseSmall MoleculeAI / ML
Technology No.
ROD01-17
Modality
Small Molecule
AI PoS
24%
Strategic Deep Dive
Repurposing Farnesyl Transferase Inhibitors for the Treatment of Cerebral Malaria
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-7 yrs
PoS24%
Market TierTier 2
Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Why this pivot works
Do not spend early capital proving a vague CNS efficacy story. First prove target engagement through a measurable rescue signal: CSF biomarker, retinal surrogate, peripheral immune marker, or metabolic precursor response that de-risks the brain hypothesis.
Capital discipline
Keep the first package biomarker-led and underpowered for efficacy; buy the right to run a real trial only after target engagement is visible.
Hurdles & Strategic Interventions
Primary BottleneckBlood-brain barrier penetration
AI Strategic InterventionUse delivery engineering, metabolic precursors, or peripheral surrogate endpoints.
Primary BottleneckClinical utility validation
AI Strategic InterventionPackage as a pharma enrichment tool before pursuing broad diagnostic reimbursement.
Buyer Map & IC Decision
Investment CommitteeLicense option
Worth a short exclusive option if diligence confirms IP scope and inventor data quality.
Attractiveness Score71/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Eli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
Biogen
CNS portfolio gap-filling and translational neurology focus.
Roche
CNS diagnostics, biomarkers, and global development scale.
Asset Attractiveness Score
71
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
80/100
Weight 15%Contribution 12 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Retrospective validation plus one pharma pilot
Use banked samples or existing datasets to prove clinical utility before paying for a prospective study.
Phase 3Prospective enrichment study with IQVIA
Run the smallest study that proves the tool improves enrollment, stratification, or decision quality.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Neurology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeEli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeBiogen
CNS portfolio gap-filling and translational neurology focus.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche
CNS diagnostics, biomarkers, and global development scale.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsMalariaa biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationMalaria
Patients already represented in banked samples, trial datasets, or partner registries.
Study designRetrospective locked-dataset validation followed by one prospective pharma enrichment pilot.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategyRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stagebiomarker validation
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Peripheral or retinal surrogate strategy
Avoid a broad CNS endpoint first; prove mechanism through a measurable proxy.
Trial-enrichment service
Sell into pharma clinical operations before attempting broad reimbursement.
Companion diagnostic option
Attach the technology to a partner drug where patient selection has immediate value.
Final Recommendation
Proceed with repositioning
Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Best next experiment
Run the smallest independent study that validates: Pair the asset with a brain-bioavailable precursor, nasal/local delivery, or exosome/nanoparticle carrier and gate spend on biomarker movement.
Best pharma targets
Eli Lilly, Biogen, Roche
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
A treatment strategy for prevention of progression of SMM/MGUS to MM without the serious side effects of painful peripheral neuropathy.
NeurologyAI / ML
Technology No.
ORL01-32
Modality
AI / ML
AI PoS
24%
Strategic Deep Dive
S-allylcysteine for Use in the Prevention and Treatment of Plasma Cell Dyscrasias
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-7 yrs
PoS24%
Market TierTier 2
Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Why this pivot works
Do not spend early capital proving a vague CNS efficacy story. First prove target engagement through a measurable rescue signal: CSF biomarker, retinal surrogate, peripheral immune marker, or metabolic precursor response that de-risks the brain hypothesis.
Capital discipline
Keep the first package biomarker-led and underpowered for efficacy; buy the right to run a real trial only after target engagement is visible.
Hurdles & Strategic Interventions
Primary BottleneckBlood-brain barrier penetration
AI Strategic InterventionUse delivery engineering, metabolic precursors, or peripheral surrogate endpoints.
Primary BottleneckClinical utility validation
AI Strategic InterventionPackage as a pharma enrichment tool before pursuing broad diagnostic reimbursement.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Eli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
Biogen
CNS portfolio gap-filling and translational neurology focus.
Roche
CNS diagnostics, biomarkers, and global development scale.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Retrospective validation plus one pharma pilot
Use banked samples or existing datasets to prove clinical utility before paying for a prospective study.
Phase 3Prospective enrichment study with IQVIA
Run the smallest study that proves the tool improves enrollment, stratification, or decision quality.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Neurology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeEli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeBiogen
CNS portfolio gap-filling and translational neurology focus.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche
CNS diagnostics, biomarkers, and global development scale.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa biomarker-defined neuroinflammation or neurodegeneration subgroupa biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa biomarker-defined neuroinflammation or neurodegeneration subgroup
Patients already represented in banked samples, trial datasets, or partner registries.
Study designRetrospective locked-dataset validation followed by one prospective pharma enrichment pilot.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategyRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stagebiomarker validation
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Peripheral or retinal surrogate strategy
Avoid a broad CNS endpoint first; prove mechanism through a measurable proxy.
Trial-enrichment service
Sell into pharma clinical operations before attempting broad reimbursement.
Companion diagnostic option
Attach the technology to a partner drug where patient selection has immediate value.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Best next experiment
Run the smallest independent study that validates: Pair the asset with a brain-bioavailable precursor, nasal/local delivery, or exosome/nanoparticle carrier and gate spend on biomarker movement.
Best pharma targets
Eli Lilly, Biogen, Roche
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
An innovative and efficacious oral treatment for bone and mineral diseases.
Technology No.
PAR07-01
Modality
Research platform
AI PoS
22%
Strategic Deep Dive
Salt-Inducible Kinase Activators to Treat Bone and Mineral Diseases
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score63/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Novartis
Broad modality appetite and academic-origin BD history.
Takeda
Translational science focus and partnership-friendly structure.
Sanofi
Immunology, rare disease, and platform-technology BD appetite.
Asset Attractiveness Score
63
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
62/100
Weight 15%Contribution 9 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
62/100
Weight 15%Contribution 9 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp specialty therapeutics wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeNovartis
Broad modality appetite and academic-origin BD history.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeTakeda
Translational science focus and partnership-friendly structure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeSanofi
Immunology, rare disease, and platform-technology BD appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsthe narrowest patient segment where the mechanism can create a measurable signal quicklya biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationthe narrowest patient segment where the mechanism can create a measurable signal quickly
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Hold until more data
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Novartis, Takeda, Sanofi
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
An innovative and efficacious treatment targeting the genetic drivers of arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D).
CardiometabolicCell/Gene Therapy
Technology No.
DEL05-02
Modality
Cell/Gene Therapy
AI PoS
23%
Strategic Deep Dive
Screening Method and Gene Therapy Approach for Treating Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia (ARVC/D)
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 3
AI-Optimized Strategy Track
Time to Market5-7 yrs
PoS23%
Market TierTier 2
Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero
Why this pivot works
The scientific upside is high, but manufacturing can consume the company. Pick one genetically crisp patient segment, one potency assay, and one CDMO process before trying to build a platform narrative.
Capital discipline
Avoid internal manufacturing buildout; spend on binder validation, potency assay reproducibility, and a narrow IND package.
Hurdles & Strategic Interventions
Primary BottleneckManufacturing complexity
AI Strategic InterventionMatch early with a cell/gene CDMO and lock a scalable release assay.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Roche Diagnostics
Companion diagnostic and translational biomarker fit.
Thermo Fisher
Research-tool commercialization and pharma services channels.
Illumina / Tempus
Data, sequencing, and clinical decision-support adjacency.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical Validation Partner
Medpace, Precision for Medicine, Q2 Solutions
Biomarker validation and sample logistics
Cell/Gene CDMO
Lonza, Catalent, Thermo Fisher
Vector, cell processing, potency assays
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Binder, potency assay, and CMC feasibility with Charles River
Gate the program on reproducible potency and manufacturability before expensive IND-enabling tox.
Phase 3Orphan Phase 1b signal trial with Medpace
Target a genetically defined cohort where a small response signal can trigger pharma partnering.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Cardiometabolic wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeRoche Diagnostics
Companion diagnostic and translational biomarker fit.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeThermo Fisher
Research-tool commercialization and pharma services channels.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeIllumina / Tempus
Data, sequencing, and clinical decision-support adjacency.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsthe narrowest patient segment where the mechanism can create a measurable signal quicklya biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationthe narrowest patient segment where the mechanism can create a measurable signal quickly
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zeroRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero
Best next experiment
Run the smallest independent study that validates: Use a centralized CDMO, lock the release assay early, and design the first trial around tumor-antigen evidence rather than broad basket ambition.
Best pharma targets
Roche Diagnostics, Thermo Fisher, Illumina / Tempus
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Sindbis Virus-Based Vectors for the Oncolytic Immunotherapy of Solid Tumors
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 2
AI-Optimized Strategy Track
Time to Market4-6 yrs
PoS30%
Market TierTier 2
Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Why this pivot works
Broad infectious-disease commercialization is brutal. The efficient path is a narrow, high-urgency segment where susceptibility, animal models, and compassionate-use logic can create a fast BD narrative.
Capital discipline
Spend first on microbiology proof and non-dilutive grant leverage; defer expensive GLP tox until the pathogen wedge is obvious.
Hurdles & Strategic Interventions
Primary BottleneckManufacturing complexity
AI Strategic InterventionMatch early with a cell/gene CDMO and lock a scalable release assay.
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Manufacturing and oncology BD infrastructure already exists.
Regeneron
Deep oncology biologics and T-cell engager adjacency.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
Cell/Gene CDMO
Lonza, Catalent, Thermo Fisher
Vector, cell processing, potency assays
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Binder, potency assay, and CMC feasibility with Charles River
Gate the program on reproducible potency and manufacturability before expensive IND-enabling tox.
Phase 3Orphan Phase 1b signal trial with IQVIA
Target a genetically defined cohort where a small response signal can trigger pharma partnering.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeGilead / Kite
Manufacturing and oncology BD infrastructure already exists.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRegeneron
Deep oncology biologics and T-cell engager adjacency.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsCancera biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationCancer
Molecularly defined patients with target expression, immune context, or resistance biology.
Study designBiomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launchRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Best next experiment
Run the smallest independent study that validates: Run pathogen-panel susceptibility, resistance mapping, and one translational model before any broad tox spend.
Best pharma targets
BMS / 2seventy, Gilead / Kite, Regeneron
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Innovative approaches to combat antibiotic resistance and enhance efficacy of existing antibiotics, particularly against biofilm-encased and persister bacteria.
Infectious DiseaseSmall MoleculeAI / ML
Technology No.
NUD01-10-18
Modality
Small Molecule
AI PoS
30%
Strategic Deep Dive
Small Molecule Inhibitors of Bacterial CSE for Treatment of Diverse Antibiotic-Resistant Infections
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market4-6 yrs
PoS30%
Market TierTier 2
Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Why this pivot works
Broad infectious-disease commercialization is brutal. The efficient path is a narrow, high-urgency segment where susceptibility, animal models, and compassionate-use logic can create a fast BD narrative.
Capital discipline
Spend first on microbiology proof and non-dilutive grant leverage; defer expensive GLP tox until the pathogen wedge is obvious.
Hurdles & Strategic Interventions
Primary BottleneckClinical utility validation
AI Strategic InterventionPackage as a pharma enrichment tool before pursuing broad diagnostic reimbursement.
Buyer Map & IC Decision
Investment CommitteeLicense option
Worth a short exclusive option if diligence confirms IP scope and inventor data quality.
Attractiveness Score71/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
GSK
Vaccines and anti-infective infrastructure.
Pfizer
Hospital, anti-infective, and vaccine commercial reach.
Johnson & Johnson
Pathogen-focused development and global health channels.
Asset Attractiveness Score
71
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
80/100
Weight 15%Contribution 12 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Retrospective validation plus one pharma pilot
Use banked samples or existing datasets to prove clinical utility before paying for a prospective study.
Phase 3Prospective enrichment study with IQVIA
Run the smallest study that proves the tool improves enrollment, stratification, or decision quality.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Infectious Disease wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeGSK
Vaccines and anti-infective infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseePfizer
Hospital, anti-infective, and vaccine commercial reach.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeJohnson & Johnson
Pathogen-focused development and global health channels.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa resistant-pathogen niche with high unmet need and grant leveragea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa resistant-pathogen niche with high unmet need and grant leverage
Patients already represented in banked samples, trial datasets, or partner registries.
Study designRetrospective locked-dataset validation followed by one prospective pharma enrichment pilot.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launchRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stagebiomarker validation
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Trial-enrichment service
Sell into pharma clinical operations before attempting broad reimbursement.
Companion diagnostic option
Attach the technology to a partner drug where patient selection has immediate value.
Final Recommendation
Proceed with repositioning
Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Best next experiment
Run the smallest independent study that validates: Run pathogen-panel susceptibility, resistance mapping, and one translational model before any broad tox spend.
Best pharma targets
GSK, Pfizer, Johnson & Johnson
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Small Molecule Inhibitors of SPNS2 for the Treatment of Chronic Inflammatory Diseases
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Novartis
Broad modality appetite and academic-origin BD history.
Takeda
Translational science focus and partnership-friendly structure.
Sanofi
Immunology, rare disease, and platform-technology BD appetite.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Inflammation wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeNovartis
Broad modality appetite and academic-origin BD history.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeTakeda
Translational science focus and partnership-friendly structure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeSanofi
Immunology, rare disease, and platform-technology BD appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsInflammatory diseasea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationInflammatory disease
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Novartis, Takeda, Sanofi
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Innovative methods to modulate host T regulatory (Treg) and Th17 cells in autoimmune disease treatment.
ImmunologyInflammation
Technology No.
LIT01-13
Modality
Cell engineering platform
AI PoS
22%
Strategic Deep Dive
Steroid Modulators of Treg Lymphocytes and Pro-Inflammatory T Helper Cells For Autoimmune Disease
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Novartis
Broad modality appetite and academic-origin BD history.
Takeda
Translational science focus and partnership-friendly structure.
Sanofi
Immunology, rare disease, and platform-technology BD appetite.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Immunology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeNovartis
Broad modality appetite and academic-origin BD history.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeTakeda
Translational science focus and partnership-friendly structure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeSanofi
Immunology, rare disease, and platform-technology BD appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsAutoimmune diseasea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationAutoimmune disease
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Novartis, Takeda, Sanofi
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Novel research tool and therapeutic approach to address the effects of aneuploidy on cancer progression and survival.
Oncology
Technology No.
DAV06-15
Modality
Research platform
AI PoS
22%
Strategic Deep Dive
Strategies to Identify and Target Aneuploidy-Associated Vulnerabilities in Lung Cancer
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
Hurdles & Strategic Interventions
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsLung cancera biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationLung cancer
Molecularly defined patients with target expression, immune context, or resistance biology.
Study designBiomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
A promising therapeutic target for the prevention and/or treatment of neurodegenerative diseases.
InflammationNeurologySmall Molecule
Technology No.
LI06-03
Modality
Small Molecule
AI PoS
24%
Strategic Deep Dive
Succinate Receptor 1 (SUCNR1) Antagonists to Treat Neuroinflammation
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-7 yrs
PoS24%
Market TierTier 2
Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Why this pivot works
Do not spend early capital proving a vague CNS efficacy story. First prove target engagement through a measurable rescue signal: CSF biomarker, retinal surrogate, peripheral immune marker, or metabolic precursor response that de-risks the brain hypothesis.
Capital discipline
Keep the first package biomarker-led and underpowered for efficacy; buy the right to run a real trial only after target engagement is visible.
Hurdles & Strategic Interventions
Primary BottleneckBlood-brain barrier penetration
AI Strategic InterventionUse delivery engineering, metabolic precursors, or peripheral surrogate endpoints.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Eli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
Biogen
CNS portfolio gap-filling and translational neurology focus.
Roche
CNS diagnostics, biomarkers, and global development scale.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Inflammation wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeEli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeBiogen
CNS portfolio gap-filling and translational neurology focus.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche
CNS diagnostics, biomarkers, and global development scale.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa biomarker-defined neuroinflammation or neurodegeneration subgroupa biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa biomarker-defined neuroinflammation or neurodegeneration subgroup
Patients stratified by CSF, imaging, genetic, retinal, inflammatory, or metabolic markers.
Study designMechanism-first biomarker study before any broad symptomatic endpoint trial.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategyRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Peripheral or retinal surrogate strategy
Avoid a broad CNS endpoint first; prove mechanism through a measurable proxy.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Best next experiment
Run the smallest independent study that validates: Pair the asset with a brain-bioavailable precursor, nasal/local delivery, or exosome/nanoparticle carrier and gate spend on biomarker movement.
Best pharma targets
Eli Lilly, Biogen, Roche
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
A series of small molecule modulators (agonists and antagonists) of TET2 for potential use as therapeutics for rare hematological diseases.
OncologyInflammationSmall Molecule
Technology No.
AIF01-09
Modality
Small Molecule
AI PoS
22%
Strategic Deep Dive
TET2 Modulators for the Treatment of Cancer and Inflammatory Diseases
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
Hurdles & Strategic Interventions
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsInflammatory diseasea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationInflammatory disease
Molecularly defined patients with target expression, immune context, or resistance biology.
Study designBiomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Targeting Endocytosis in Nociceptors as a Non-Opioid Treatment Strategy for Chronic Pain
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-7 yrs
PoS24%
Market TierTier 2
Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Why this pivot works
Do not spend early capital proving a vague CNS efficacy story. First prove target engagement through a measurable rescue signal: CSF biomarker, retinal surrogate, peripheral immune marker, or metabolic precursor response that de-risks the brain hypothesis.
Capital discipline
Keep the first package biomarker-led and underpowered for efficacy; buy the right to run a real trial only after target engagement is visible.
Hurdles & Strategic Interventions
Primary BottleneckBlood-brain barrier penetration
AI Strategic InterventionUse delivery engineering, metabolic precursors, or peripheral surrogate endpoints.
Primary BottleneckClinical utility validation
AI Strategic InterventionPackage as a pharma enrichment tool before pursuing broad diagnostic reimbursement.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Eli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
Biogen
CNS portfolio gap-filling and translational neurology focus.
Roche
CNS diagnostics, biomarkers, and global development scale.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Retrospective validation plus one pharma pilot
Use banked samples or existing datasets to prove clinical utility before paying for a prospective study.
Phase 3Prospective enrichment study with IQVIA
Run the smallest study that proves the tool improves enrollment, stratification, or decision quality.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Neurology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeEli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeBiogen
CNS portfolio gap-filling and translational neurology focus.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche
CNS diagnostics, biomarkers, and global development scale.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa biomarker-defined neuroinflammation or neurodegeneration subgroupa biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa biomarker-defined neuroinflammation or neurodegeneration subgroup
Patients already represented in banked samples, trial datasets, or partner registries.
Study designRetrospective locked-dataset validation followed by one prospective pharma enrichment pilot.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategyRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stagebiomarker validation
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Peripheral or retinal surrogate strategy
Avoid a broad CNS endpoint first; prove mechanism through a measurable proxy.
Trial-enrichment service
Sell into pharma clinical operations before attempting broad reimbursement.
Companion diagnostic option
Attach the technology to a partner drug where patient selection has immediate value.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Best next experiment
Run the smallest independent study that validates: Pair the asset with a brain-bioavailable precursor, nasal/local delivery, or exosome/nanoparticle carrier and gate spend on biomarker movement.
Best pharma targets
Eli Lilly, Biogen, Roche
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Innovative therapeutic strategy to promote antigen presentation in immunologically “cold” tumors.
OncologyImmunology
Technology No.
WAN05-08
Modality
Research platform
AI PoS
22%
Strategic Deep Dive
Targeting MHC-1 Antigen Presentation Machinery for Cancer Immunotherapy
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
Hurdles & Strategic Interventions
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsCancera biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationCancer
Molecularly defined patients with target expression, immune context, or resistance biology.
Study designBiomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
New and effective treatments for COVID-19 and other viral infections caused by RNA viruses.
Infectious DiseaseSmall Molecule
Technology No.
MOH02-08
Modality
Small Molecule
AI PoS
30%
Strategic Deep Dive
Targeting RNA Viruses Using Inhibitors of METTL3
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market4-6 yrs
PoS30%
Market TierTier 2
Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Why this pivot works
Broad infectious-disease commercialization is brutal. The efficient path is a narrow, high-urgency segment where susceptibility, animal models, and compassionate-use logic can create a fast BD narrative.
Capital discipline
Spend first on microbiology proof and non-dilutive grant leverage; defer expensive GLP tox until the pathogen wedge is obvious.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
GSK
Vaccines and anti-infective infrastructure.
Pfizer
Hospital, anti-infective, and vaccine commercial reach.
Johnson & Johnson
Pathogen-focused development and global health channels.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Infectious Disease wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeGSK
Vaccines and anti-infective infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseePfizer
Hospital, anti-infective, and vaccine commercial reach.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeJohnson & Johnson
Pathogen-focused development and global health channels.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsCOVID-19a biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationCOVID-19
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launchRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Best next experiment
Run the smallest independent study that validates: Run pathogen-panel susceptibility, resistance mapping, and one translational model before any broad tox spend.
Best pharma targets
GSK, Pfizer, Johnson & Johnson
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
New and innovative therapeutic approaches for efficient PDAC treatment
Cardiometabolic
Technology No.
KIM06-01
Modality
Research platform
AI PoS
22%
Strategic Deep Dive
Targeting a Novel Metabolic Network for Pancreatic Ductal Adenocarcinoma (PDAC) Treatment
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Novartis
Broad modality appetite and academic-origin BD history.
Takeda
Translational science focus and partnership-friendly structure.
Sanofi
Immunology, rare disease, and platform-technology BD appetite.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Cardiometabolic wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeNovartis
Broad modality appetite and academic-origin BD history.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeTakeda
Translational science focus and partnership-friendly structure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeSanofi
Immunology, rare disease, and platform-technology BD appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsthe narrowest patient segment where the mechanism can create a measurable signal quicklya biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationthe narrowest patient segment where the mechanism can create a measurable signal quickly
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Novartis, Takeda, Sanofi
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Targeted therapies that specifically modulate epithelial and hair follicle–driven inflammation in hidradenitis suppurativa and related hair disorders without broad systemic immunosuppression.
InflammationAI / ML
Technology No.
PET03-03
Modality
AI / ML
AI PoS
45%
Strategic Deep Dive
Targeting the CXCR4-CD74 Heterodimer as a Therapeutic Strategy for Hidradenitis Suppurativa and Male Pattern Hair Loss
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market2-4 yrs
PoS45%
Market TierTier 1
Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Why this pivot works
Reimbursement can wait. The cash-efficient path is to sell the technology as a trial-enrichment, patient-stratification, or translational biomarker service to pharma teams that already have trial budgets.
Capital discipline
Use fee-for-service pilots to fund validation; avoid building a regulated diagnostic company before buyer pull is proven.
Hurdles & Strategic Interventions
Primary BottleneckClinical utility validation
AI Strategic InterventionPackage as a pharma enrichment tool before pursuing broad diagnostic reimbursement.
Buyer Map & IC Decision
Investment CommitteeLicense option
Worth a short exclusive option if diligence confirms IP scope and inventor data quality.
Attractiveness Score72/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Roche Diagnostics
Companion diagnostic and translational biomarker fit.
Thermo Fisher
Research-tool commercialization and pharma services channels.
Illumina / Tempus
Data, sequencing, and clinical decision-support adjacency.
Asset Attractiveness Score
72
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
84/100
Weight 10%Contribution 8 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
86/100
Weight 10%Contribution 9 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Retrospective validation plus one pharma pilot
Use banked samples or existing datasets to prove clinical utility before paying for a prospective study.
Phase 3Prospective enrichment study with IQVIA
Run the smallest study that proves the tool improves enrollment, stratification, or decision quality.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Inflammation wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeRoche Diagnostics
Companion diagnostic and translational biomarker fit.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeThermo Fisher
Research-tool commercialization and pharma services channels.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeIllumina / Tempus
Data, sequencing, and clinical decision-support adjacency.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa pharma trial-enrichment use case before broad diagnostic commercializationa biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa pharma trial-enrichment use case before broad diagnostic commercialization
Patients already represented in banked samples, trial datasets, or partner registries.
Study designRetrospective locked-dataset validation followed by one prospective pharma enrichment pilot.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Monetize first as a pharma enrichment engine, not a reimbursed diagnosticRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stagebiomarker validation
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Trial-enrichment service
Sell into pharma clinical operations before attempting broad reimbursement.
Companion diagnostic option
Attach the technology to a partner drug where patient selection has immediate value.
Final Recommendation
Proceed with repositioning
Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Best next experiment
Run the smallest independent study that validates: Package the model or assay with a locked validation dataset, CLIA/service workflow, and one sponsor-ready use case.
Best pharma targets
Roche Diagnostics, Thermo Fisher, Illumina / Tempus
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
New and innovative therapeutic approaches for blocking SARS-CoV-2 engagement with immune cells
ImmunologyInfectious Disease
Technology No.
WAN05-01
Modality
Cell engineering platform
AI PoS
30%
Strategic Deep Dive
Targeting the SARS-CoV-2 Viral-Immune Interaction for COVID-19 Therapy
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market4-6 yrs
PoS30%
Market TierTier 2
Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Why this pivot works
Broad infectious-disease commercialization is brutal. The efficient path is a narrow, high-urgency segment where susceptibility, animal models, and compassionate-use logic can create a fast BD narrative.
Capital discipline
Spend first on microbiology proof and non-dilutive grant leverage; defer expensive GLP tox until the pathogen wedge is obvious.
AI Strategic InterventionCompress diligence by outsourcing tox, CMC, and first indication selection in parallel.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
GSK
Vaccines and anti-infective infrastructure.
Pfizer
Hospital, anti-infective, and vaccine commercial reach.
Johnson & Johnson
Pathogen-focused development and global health channels.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Immunology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeGSK
Vaccines and anti-infective infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseePfizer
Hospital, anti-infective, and vaccine commercial reach.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeJohnson & Johnson
Pathogen-focused development and global health channels.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsCOVID-19a biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationCOVID-19
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launchRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Best next experiment
Run the smallest independent study that validates: Run pathogen-panel susceptibility, resistance mapping, and one translational model before any broad tox spend.
Best pharma targets
GSK, Pfizer, Johnson & Johnson
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
A novel therapeutic approach for treating patients who do not respond to front-line immunotherapies.
Oncology
Technology No.
PAP02-05
Modality
Research platform
AI PoS
22%
Strategic Deep Dive
Targeting the Stress-Response Pathway to Promote Anti-tumor Responses
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
Hurdles & Strategic Interventions
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa molecularly selected tumor segment where a small proof-of-mechanism study is crediblea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa molecularly selected tumor segment where a small proof-of-mechanism study is credible
Molecularly defined patients with target expression, immune context, or resistance biology.
Study designBiomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Innovative disease-modifying method to treat knee cartilage injuries and prevent development of post-traumatic osteoarthritis (PTOA)
InflammationBiologicAI / ML
Technology No.
COW02-02
Modality
Biologic
AI PoS
45%
Strategic Deep Dive
Therapeutic Hyaluronic Acid and Peptide Composition for Regenerative Repair of Cartilage Injury
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market2-4 yrs
PoS45%
Market TierTier 1
Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Why this pivot works
Reimbursement can wait. The cash-efficient path is to sell the technology as a trial-enrichment, patient-stratification, or translational biomarker service to pharma teams that already have trial budgets.
Capital discipline
Use fee-for-service pilots to fund validation; avoid building a regulated diagnostic company before buyer pull is proven.
Hurdles & Strategic Interventions
Primary BottleneckClinical utility validation
AI Strategic InterventionPackage as a pharma enrichment tool before pursuing broad diagnostic reimbursement.
Buyer Map & IC Decision
Investment CommitteePartner outreach
Strong enough to test buyer appetite now while validating the cheapest decisive experiment.
Attractiveness Score74/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Roche Diagnostics
Companion diagnostic and translational biomarker fit.
Thermo Fisher
Research-tool commercialization and pharma services channels.
Illumina / Tempus
Data, sequencing, and clinical decision-support adjacency.
Asset Attractiveness Score
74
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
80/100
Weight 15%Contribution 12 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
84/100
Weight 10%Contribution 8 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
86/100
Weight 10%Contribution 9 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Retrospective validation plus one pharma pilot
Use banked samples or existing datasets to prove clinical utility before paying for a prospective study.
Phase 3Prospective enrichment study with IQVIA
Run the smallest study that proves the tool improves enrollment, stratification, or decision quality.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Inflammation wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeRoche Diagnostics
Companion diagnostic and translational biomarker fit.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeThermo Fisher
Research-tool commercialization and pharma services channels.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeIllumina / Tempus
Data, sequencing, and clinical decision-support adjacency.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa pharma trial-enrichment use case before broad diagnostic commercializationa biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa pharma trial-enrichment use case before broad diagnostic commercialization
Patients already represented in banked samples, trial datasets, or partner registries.
Study designRetrospective locked-dataset validation followed by one prospective pharma enrichment pilot.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Monetize first as a pharma enrichment engine, not a reimbursed diagnosticRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stagebiomarker validation
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Trial-enrichment service
Sell into pharma clinical operations before attempting broad reimbursement.
Companion diagnostic option
Attach the technology to a partner drug where patient selection has immediate value.
Final Recommendation
Proceed
Strong enough to test buyer appetite now while validating the cheapest decisive experiment. The most investable version is: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Best next experiment
Run the smallest independent study that validates: Package the model or assay with a locked validation dataset, CLIA/service workflow, and one sponsor-ready use case.
Best pharma targets
Roche Diagnostics, Thermo Fisher, Illumina / Tempus
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Therapeutic Targeting of KMT2D Mutant Lung Cancer Via RTK-RAS Signaling Inhibition
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
Hurdles & Strategic Interventions
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsLung cancera biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationLung cancer
Molecularly defined patients with target expression, immune context, or resistance biology.
Study designBiomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Thromboinflammation Platelet Signatures (TIPS): A Novel Biomarker for Cardiovascular Disease
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 3
AI-Optimized Strategy Track
Time to Market2-4 yrs
PoS45%
Market TierTier 1
Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Why this pivot works
Reimbursement can wait. The cash-efficient path is to sell the technology as a trial-enrichment, patient-stratification, or translational biomarker service to pharma teams that already have trial budgets.
Capital discipline
Use fee-for-service pilots to fund validation; avoid building a regulated diagnostic company before buyer pull is proven.
Hurdles & Strategic Interventions
Primary BottleneckClinical utility validation
AI Strategic InterventionPackage as a pharma enrichment tool before pursuing broad diagnostic reimbursement.
Buyer Map & IC Decision
Investment CommitteePartner outreach
Strong enough to test buyer appetite now while validating the cheapest decisive experiment.
Attractiveness Score76/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Roche Diagnostics
Companion diagnostic and translational biomarker fit.
Thermo Fisher
Research-tool commercialization and pharma services channels.
Illumina / Tempus
Data, sequencing, and clinical decision-support adjacency.
Asset Attractiveness Score
76
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
82/100
Weight 15%Contribution 12 pts
Differentiation
How clearly the technology can be positioned as different.
80/100
Weight 15%Contribution 12 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
84/100
Weight 10%Contribution 8 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
86/100
Weight 10%Contribution 9 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical Validation Partner
Medpace, Precision for Medicine, Q2 Solutions
Biomarker validation and sample logistics
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Retrospective validation plus one pharma pilot
Use banked samples or existing datasets to prove clinical utility before paying for a prospective study.
Phase 3Prospective enrichment study with Medpace
Run the smallest study that proves the tool improves enrollment, stratification, or decision quality.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Inflammation wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeRoche Diagnostics
Companion diagnostic and translational biomarker fit.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeThermo Fisher
Research-tool commercialization and pharma services channels.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeIllumina / Tempus
Data, sequencing, and clinical decision-support adjacency.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa pharma trial-enrichment use case before broad diagnostic commercializationa biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa pharma trial-enrichment use case before broad diagnostic commercialization
Patients already represented in banked samples, trial datasets, or partner registries.
Study designRetrospective locked-dataset validation followed by one prospective pharma enrichment pilot.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Monetize first as a pharma enrichment engine, not a reimbursed diagnosticRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stagebiomarker validation
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Trial-enrichment service
Sell into pharma clinical operations before attempting broad reimbursement.
Companion diagnostic option
Attach the technology to a partner drug where patient selection has immediate value.
Final Recommendation
Proceed
Strong enough to test buyer appetite now while validating the cheapest decisive experiment. The most investable version is: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Best next experiment
Run the smallest independent study that validates: Package the model or assay with a locked validation dataset, CLIA/service workflow, and one sponsor-ready use case.
Best pharma targets
Roche Diagnostics, Thermo Fisher, Illumina / Tempus
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
An effective, differentiated, and targeted therapeutic strategy for the treatment of inflammatory skin diseases such as psoriasis, atopic dermatitis, and hidradenitis suppurativa.
InflammationDrug Delivery
Technology No.
NAI02-03
Modality
Drug Delivery
AI PoS
28%
Strategic Deep Dive
Topical Inhibition of HIF-1a as a Novel Therapeutic Strategy for Inflammatory Skin Diseases
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market5-6 yrs
PoS28%
Market TierTier 2
Turn delivery into the asset by choosing a toxicity-sensitive local indication
Why this pivot works
A delivery technology wins when it solves a painful tradeoff: high local exposure with low systemic burden. Pick an indication where reduced dose, fewer adverse events, or easier administration is the buyer's actual reason to care.
Capital discipline
Use a validated payload and small PK package; do not fund broad platform claims until one local-use case works.
Hurdles & Strategic Interventions
Primary BottleneckFormulation and biodistribution risk
AI Strategic InterventionMove to localized administration and validate exposure with a focused PK package.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Novartis
Broad modality appetite and academic-origin BD history.
Takeda
Translational science focus and partnership-friendly structure.
Sanofi
Immunology, rare disease, and platform-technology BD appetite.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Turn delivery into the asset by choosing a toxicity-sensitive local indication. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Inflammation wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeNovartis
Broad modality appetite and academic-origin BD history.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeTakeda
Translational science focus and partnership-friendly structure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeSanofi
Immunology, rare disease, and platform-technology BD appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsInflammatory diseasea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationInflammatory disease
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Turn delivery into the asset by choosing a toxicity-sensitive local indicationRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Turn delivery into the asset by choosing a toxicity-sensitive local indication
New delivery route
Pair the delivery system with a known payload and prove exposure advantage in a local indication.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Turn delivery into the asset by choosing a toxicity-sensitive local indication
Best next experiment
Run the smallest independent study that validates: Run biodistribution and local tolerability first, then attach the platform to a known active payload instead of inventing a new drug story.
Best pharma targets
Novartis, Takeda, Sanofi
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Transgenic mouse model expressing a human uromodulin mutant mimicking hereditary human mutant uromodulin caused kidney diseases for testing diagnostics and therapy.
CardiometabolicDiagnostic / Biomarker
Technology No.
WU01-01
Modality
Diagnostic / Biomarker
AI PoS
45%
Strategic Deep Dive
Transgenic Mouse Model Expressing C217G Uromodulin
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market7-9 yrs
PoS12%
Market TierTier 3
AI-Optimized Strategy Track
Time to Market2-4 yrs
PoS45%
Market TierTier 1
Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Why this pivot works
Reimbursement can wait. The cash-efficient path is to sell the technology as a trial-enrichment, patient-stratification, or translational biomarker service to pharma teams that already have trial budgets.
Capital discipline
Use fee-for-service pilots to fund validation; avoid building a regulated diagnostic company before buyer pull is proven.
Hurdles & Strategic Interventions
Primary BottleneckClinical utility validation
AI Strategic InterventionPackage as a pharma enrichment tool before pursuing broad diagnostic reimbursement.
Buyer Map & IC Decision
Investment CommitteePartner outreach
Strong enough to test buyer appetite now while validating the cheapest decisive experiment.
Attractiveness Score76/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Roche Diagnostics
Companion diagnostic and translational biomarker fit.
Thermo Fisher
Research-tool commercialization and pharma services channels.
Illumina / Tempus
Data, sequencing, and clinical decision-support adjacency.
Asset Attractiveness Score
76
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
82/100
Weight 15%Contribution 12 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
70/100
Weight 10%Contribution 7 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
84/100
Weight 10%Contribution 8 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
86/100
Weight 10%Contribution 9 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical Validation Partner
Medpace, Precision for Medicine, Q2 Solutions
Biomarker validation and sample logistics
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Retrospective validation plus one pharma pilot
Use banked samples or existing datasets to prove clinical utility before paying for a prospective study.
Phase 3Prospective enrichment study with Medpace
Run the smallest study that proves the tool improves enrollment, stratification, or decision quality.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Cardiometabolic wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeRoche Diagnostics
Companion diagnostic and translational biomarker fit.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeThermo Fisher
Research-tool commercialization and pharma services channels.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeIllumina / Tempus
Data, sequencing, and clinical decision-support adjacency.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsKidney diseasea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationKidney disease
Patients already represented in banked samples, trial datasets, or partner registries.
Study designRetrospective locked-dataset validation followed by one prospective pharma enrichment pilot.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Monetize first as a pharma enrichment engine, not a reimbursed diagnosticRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stagebiomarker validation
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Trial-enrichment service
Sell into pharma clinical operations before attempting broad reimbursement.
Companion diagnostic option
Attach the technology to a partner drug where patient selection has immediate value.
Final Recommendation
Proceed
Strong enough to test buyer appetite now while validating the cheapest decisive experiment. The most investable version is: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic
Best next experiment
Run the smallest independent study that validates: Package the model or assay with a locked validation dataset, CLIA/service workflow, and one sponsor-ready use case.
Best pharma targets
Roche Diagnostics, Thermo Fisher, Illumina / Tempus
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Treatment for Alzheimer’s Disease by Inhibiting Formation of Platelet Micro-Clots
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-7 yrs
PoS24%
Market TierTier 2
Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Why this pivot works
Do not spend early capital proving a vague CNS efficacy story. First prove target engagement through a measurable rescue signal: CSF biomarker, retinal surrogate, peripheral immune marker, or metabolic precursor response that de-risks the brain hypothesis.
Capital discipline
Keep the first package biomarker-led and underpowered for efficacy; buy the right to run a real trial only after target engagement is visible.
Hurdles & Strategic Interventions
Primary BottleneckBlood-brain barrier penetration
AI Strategic InterventionUse delivery engineering, metabolic precursors, or peripheral surrogate endpoints.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Eli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
Biogen
CNS portfolio gap-filling and translational neurology focus.
Roche
CNS diagnostics, biomarkers, and global development scale.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Neurology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeEli Lilly
Neurodegeneration leadership and biomarker-driven trial infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeBiogen
CNS portfolio gap-filling and translational neurology focus.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche
CNS diagnostics, biomarkers, and global development scale.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsAlzheimer's diseasea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationAlzheimer's disease
Patients stratified by CSF, imaging, genetic, retinal, inflammatory, or metabolic markers.
Study designMechanism-first biomarker study before any broad symptomatic endpoint trial.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategyRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Peripheral or retinal surrogate strategy
Avoid a broad CNS endpoint first; prove mechanism through a measurable proxy.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Best next experiment
Run the smallest independent study that validates: Pair the asset with a brain-bioavailable precursor, nasal/local delivery, or exosome/nanoparticle carrier and gate spend on biomarker movement.
Best pharma targets
Eli Lilly, Biogen, Roche
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Treatment of Melanoma Brain Metastasis by Inhibition of Amyloid Precursor Protein Cleavage
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-7 yrs
PoS24%
Market TierTier 2
Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Why this pivot works
Do not spend early capital proving a vague CNS efficacy story. First prove target engagement through a measurable rescue signal: CSF biomarker, retinal surrogate, peripheral immune marker, or metabolic precursor response that de-risks the brain hypothesis.
Capital discipline
Keep the first package biomarker-led and underpowered for efficacy; buy the right to run a real trial only after target engagement is visible.
Hurdles & Strategic Interventions
Primary BottleneckBlood-brain barrier penetration
AI Strategic InterventionUse delivery engineering, metabolic precursors, or peripheral surrogate endpoints.
Primary BottleneckClinical utility validation
AI Strategic InterventionPackage as a pharma enrichment tool before pursuing broad diagnostic reimbursement.
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeLicense option
Worth a short exclusive option if diligence confirms IP scope and inventor data quality.
Attractiveness Score71/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
71
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
80/100
Weight 15%Contribution 12 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Retrospective validation plus one pharma pilot
Use banked samples or existing datasets to prove clinical utility before paying for a prospective study.
Phase 3Prospective enrichment study with IQVIA
Run the smallest study that proves the tool improves enrollment, stratification, or decision quality.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa biomarker-defined neuroinflammation or neurodegeneration subgroupa biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa biomarker-defined neuroinflammation or neurodegeneration subgroup
Patients already represented in banked samples, trial datasets, or partner registries.
Study designRetrospective locked-dataset validation followed by one prospective pharma enrichment pilot.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategyRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stagebiomarker validation
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Peripheral or retinal surrogate strategy
Avoid a broad CNS endpoint first; prove mechanism through a measurable proxy.
Trial-enrichment service
Sell into pharma clinical operations before attempting broad reimbursement.
Final Recommendation
Proceed with repositioning
Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy
Best next experiment
Run the smallest independent study that validates: Pair the asset with a brain-bioavailable precursor, nasal/local delivery, or exosome/nanoparticle carrier and gate spend on biomarker movement.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Tumor-Targeting Nanoparticles for Precision Chemotherapy in Cancer
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market5-6 yrs
PoS28%
Market TierTier 2
Turn delivery into the asset by choosing a toxicity-sensitive local indication
Why this pivot works
A delivery technology wins when it solves a painful tradeoff: high local exposure with low systemic burden. Pick an indication where reduced dose, fewer adverse events, or easier administration is the buyer's actual reason to care.
Capital discipline
Use a validated payload and small PK package; do not fund broad platform claims until one local-use case works.
Hurdles & Strategic Interventions
Primary BottleneckFormulation and biodistribution risk
AI Strategic InterventionMove to localized administration and validate exposure with a focused PK package.
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeLicense option
Worth a short exclusive option if diligence confirms IP scope and inventor data quality.
Attractiveness Score71/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
71
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
80/100
Weight 15%Contribution 12 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Turn delivery into the asset by choosing a toxicity-sensitive local indication. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsLiver diseasea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationLiver disease
Molecularly defined patients with target expression, immune context, or resistance biology.
Study designBiomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Turn delivery into the asset by choosing a toxicity-sensitive local indicationRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Turn delivery into the asset by choosing a toxicity-sensitive local indication
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
New delivery route
Pair the delivery system with a known payload and prove exposure advantage in a local indication.
Final Recommendation
Proceed with repositioning
Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Turn delivery into the asset by choosing a toxicity-sensitive local indication
Best next experiment
Run the smallest independent study that validates: Run biodistribution and local tolerability first, then attach the platform to a known active payload instead of inventing a new drug story.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Vector-Based Replicons for Enhanced Genetic Payload Delivery and Vaccine Formulations
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market1-3 yrs
PoS55%
Market TierTier 3
AI-Optimized Strategy Track
Time to Market5-7 yrs
PoS23%
Market TierTier 2
Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero
Why this pivot works
The scientific upside is high, but manufacturing can consume the company. Pick one genetically crisp patient segment, one potency assay, and one CDMO process before trying to build a platform narrative.
Capital discipline
Avoid internal manufacturing buildout; spend on binder validation, potency assay reproducibility, and a narrow IND package.
Hurdles & Strategic Interventions
Primary BottleneckManufacturing complexity
AI Strategic InterventionMatch early with a cell/gene CDMO and lock a scalable release assay.
Primary BottleneckFormulation and biodistribution risk
AI Strategic InterventionMove to localized administration and validate exposure with a focused PK package.
Buyer Map & IC Decision
Investment CommitteeLicense option
Worth a short exclusive option if diligence confirms IP scope and inventor data quality.
Attractiveness Score73/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Roche Diagnostics
Companion diagnostic and translational biomarker fit.
Thermo Fisher
Research-tool commercialization and pharma services channels.
Illumina / Tempus
Data, sequencing, and clinical decision-support adjacency.
Asset Attractiveness Score
73
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
80/100
Weight 15%Contribution 12 pts
Stage / data quality
How much real validation exists today.
70/100
Weight 10%Contribution 7 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical Validation Partner
Medpace, Precision for Medicine, Q2 Solutions
Biomarker validation and sample logistics
Cell/Gene CDMO
Lonza, Catalent, Thermo Fisher
Vector, cell processing, potency assays
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Binder, potency assay, and CMC feasibility with Charles River
Gate the program on reproducible potency and manufacturability before expensive IND-enabling tox.
Phase 3Orphan Phase 1b signal trial with Medpace
Target a genetically defined cohort where a small response signal can trigger pharma partnering.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Cardiometabolic wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeRoche Diagnostics
Companion diagnostic and translational biomarker fit.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeThermo Fisher
Research-tool commercialization and pharma services channels.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeIllumina / Tempus
Data, sequencing, and clinical decision-support adjacency.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsLiver diseasea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationLiver disease
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zeroRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero
New delivery route
Pair the delivery system with a known payload and prove exposure advantage in a local indication.
Final Recommendation
Proceed with repositioning
Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero
Best next experiment
Run the smallest independent study that validates: Use a centralized CDMO, lock the release assay early, and design the first trial around tumor-antigen evidence rather than broad basket ambition.
Best pharma targets
Roche Diagnostics, Thermo Fisher, Illumina / Tempus
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Innovative, alternative, and complementary treatment option for pan-coronavirus infections
Infectious DiseaseCell/Gene Therapy
Technology No.
LAN02-06
Modality
Cell/Gene Therapy
AI PoS
30%
Strategic Deep Dive
Vectored ACE2 Receptor Decoy for Prevention and Treatment of Pan-Coronavirus Infections
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market4-6 yrs
PoS30%
Market TierTier 2
Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Why this pivot works
Broad infectious-disease commercialization is brutal. The efficient path is a narrow, high-urgency segment where susceptibility, animal models, and compassionate-use logic can create a fast BD narrative.
Capital discipline
Spend first on microbiology proof and non-dilutive grant leverage; defer expensive GLP tox until the pathogen wedge is obvious.
Hurdles & Strategic Interventions
Primary BottleneckManufacturing complexity
AI Strategic InterventionMatch early with a cell/gene CDMO and lock a scalable release assay.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
GSK
Vaccines and anti-infective infrastructure.
Pfizer
Hospital, anti-infective, and vaccine commercial reach.
Johnson & Johnson
Pathogen-focused development and global health channels.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
Cell/Gene CDMO
Lonza, Catalent, Thermo Fisher
Vector, cell processing, potency assays
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Binder, potency assay, and CMC feasibility with Charles River
Gate the program on reproducible potency and manufacturability before expensive IND-enabling tox.
Phase 3Orphan Phase 1b signal trial with IQVIA
Target a genetically defined cohort where a small response signal can trigger pharma partnering.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Infectious Disease wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeGSK
Vaccines and anti-infective infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseePfizer
Hospital, anti-infective, and vaccine commercial reach.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeJohnson & Johnson
Pathogen-focused development and global health channels.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa resistant-pathogen niche with high unmet need and grant leveragea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa resistant-pathogen niche with high unmet need and grant leverage
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launchRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Best next experiment
Run the smallest independent study that validates: Run pathogen-panel susceptibility, resistance mapping, and one translational model before any broad tox spend.
Best pharma targets
GSK, Pfizer, Johnson & Johnson
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Innovative and targeted approaches to treat perceptual deficits associated with reduced GABA receptor-mediated inhibitory postsynaptic potentials.
Infectious DiseaseSmall MoleculeCell/Gene Therapy
Technology No.
SAN06-01
Modality
Small Molecule
AI PoS
30%
Strategic Deep Dive
Viral Vector Expression of Gabrb1b for the Treatment of Perceptual Deficits
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market4-6 yrs
PoS30%
Market TierTier 2
Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Why this pivot works
Broad infectious-disease commercialization is brutal. The efficient path is a narrow, high-urgency segment where susceptibility, animal models, and compassionate-use logic can create a fast BD narrative.
Capital discipline
Spend first on microbiology proof and non-dilutive grant leverage; defer expensive GLP tox until the pathogen wedge is obvious.
Hurdles & Strategic Interventions
Primary BottleneckManufacturing complexity
AI Strategic InterventionMatch early with a cell/gene CDMO and lock a scalable release assay.
Buyer Map & IC Decision
Investment CommitteeLicense option
Worth a short exclusive option if diligence confirms IP scope and inventor data quality.
Attractiveness Score71/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
GSK
Vaccines and anti-infective infrastructure.
Pfizer
Hospital, anti-infective, and vaccine commercial reach.
Johnson & Johnson
Pathogen-focused development and global health channels.
Asset Attractiveness Score
71
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
80/100
Weight 15%Contribution 12 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
Cell/Gene CDMO
Lonza, Catalent, Thermo Fisher
Vector, cell processing, potency assays
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Binder, potency assay, and CMC feasibility with Charles River
Gate the program on reproducible potency and manufacturability before expensive IND-enabling tox.
Phase 3Orphan Phase 1b signal trial with IQVIA
Target a genetically defined cohort where a small response signal can trigger pharma partnering.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Infectious Disease wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeGSK
Vaccines and anti-infective infrastructure.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseePfizer
Hospital, anti-infective, and vaccine commercial reach.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeJohnson & Johnson
Pathogen-focused development and global health channels.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa resistant-pathogen niche with high unmet need and grant leveragea biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa resistant-pathogen niche with high unmet need and grant leverage
A narrow segment with the clearest biology, fastest endpoint, and strongest partner relevance.
Study designOne decisive preclinical or analytical validation package with a hard go/no-go threshold.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launchRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Narrow indication reset
Pick one buyer, one patient segment, and one decisive experiment before selling a broad platform story.
505(b)(2) or known-payload pairing
If applicable, reduce biology risk by pairing the invention with an established active ingredient or mechanism.
Final Recommendation
Proceed with repositioning
Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch
Best next experiment
Run the smallest independent study that validates: Run pathogen-panel susceptibility, resistance mapping, and one translational model before any broad tox spend.
Best pharma targets
GSK, Pfizer, Johnson & Johnson
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
Robust and innovative method for accurate classification of AML patients to enable personalized treatment approaches
Oncology
Technology No.
AIF01-12
Modality
Research platform
AI PoS
22%
Strategic Deep Dive
iScore: A Novel Method for Improved Risk Stratification of AML Patients
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 4
AI-Optimized Strategy Track
Time to Market6-8 yrs
PoS22%
Market TierTier 3
Indication narrowing plus an outsourced translational evidence package
Why this pivot works
The core move is to stop treating the invention like a broad academic platform. Pick one buyer, one indication, one decisive experiment, and one partnerable milestone.
Capital discipline
Stage capital through hard gates: literature/IP diligence, one decisive in vivo or analytical validation study, then BD outreach before expensive scale-up.
Hurdles & Strategic Interventions
Primary BottleneckCrowded oncology development path
AI Strategic InterventionNarrow to biomarker-selected or orphan populations with visible pharma appetite.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score69/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Merck
Checkpoint-franchise adjacency and combination-trial appetite.
AstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
Roche / Genentech
Diagnostics plus oncology translational machinery.
Asset Attractiveness Score
69
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
78/100
Weight 15%Contribution 12 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
64/100
Weight 15%Contribution 10 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical CRO
IQVIA, ICON, Medpace
Phase 1b/2a protocol design and site execution
CDMO
Lonza, Catalent, Evonik
CMC, scale-up, formulation, release testing
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Indication narrowing plus an outsourced translational evidence package. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Preclinical IND-Enabling Runway with Charles River
Run tox, PK/PD, CMC gap closure, and a single decisive go/no-go efficacy package.
Phase 3Phase 1b/2a Value Inflection Trial with IQVIA
Generate signal in a narrow, high-value patient segment rather than proving broad platform potential.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeMerck
Checkpoint-franchise adjacency and combination-trial appetite.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeAstraZeneca
Oncology breadth plus interest in biomarker-defined populations.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeRoche / Genentech
Diagnostics plus oncology translational machinery.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsAcute myeloid leukemiaa biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationAcute myeloid leukemia
Molecularly defined patients with target expression, immune context, or resistance biology.
Study designBiomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence packageRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stageIND-enabling proof package
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Indication narrowing plus an outsourced translational evidence package
Biomarker-enriched oncology wedge
Prioritize a molecularly defined subgroup where a small trial can look meaningful.
Combination with existing standard-of-care
Make the asset valuable as a lifecycle or resistance strategy for pharma portfolios.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Indication narrowing plus an outsourced translational evidence package
Best next experiment
Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.
Best pharma targets
Merck, AstraZeneca, Roche / Genentech
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
A highly specific and tailorable transgene expression systems compatible with conventional gene therapy platforms
Small MoleculeCell/Gene TherapyAI / ML
Technology No.
TEN01-04
Modality
Small Molecule
AI PoS
23%
Strategic Deep Dive
miRNA-Mediated Transgene Expression System for Improved Gene Therapies and Research Reagent Applications
License-Rx Strategy
Classifier
Modality, target, stage, IP, missing data
Landscape
Approved products, clinical pipeline, failed assets, white space
BD Strategy
Best indication, combo logic, buyer fit, packaging
Development Plan
Killer experiment, budget gate, regulatory path
IC Judge
Pass/watchlist/option/spinout/outreach decision
As-Is University Track
Time to Market10-12 yrs
PoS8%
Market TierTier 3
AI-Optimized Strategy Track
Time to Market5-7 yrs
PoS23%
Market TierTier 2
Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero
Why this pivot works
The scientific upside is high, but manufacturing can consume the company. Pick one genetically crisp patient segment, one potency assay, and one CDMO process before trying to build a platform narrative.
Capital discipline
Avoid internal manufacturing buildout; spend on binder validation, potency assay reproducibility, and a narrow IND package.
Hurdles & Strategic Interventions
Primary BottleneckManufacturing complexity
AI Strategic InterventionMatch early with a cell/gene CDMO and lock a scalable release assay.
Primary BottleneckClinical utility validation
AI Strategic InterventionPackage as a pharma enrichment tool before pursuing broad diagnostic reimbursement.
Buyer Map & IC Decision
Investment CommitteeSponsored research
Interesting science, but the next dataset should be funded before committing to a full license.
Attractiveness Score68/100
Weighted by unmet need, white space, differentiation, data quality, IP, feasibility, buyer fit, and near-term inflection.
Likely Buyer
Why They Might Care
Roche Diagnostics
Companion diagnostic and translational biomarker fit.
Thermo Fisher
Research-tool commercialization and pharma services channels.
Illumina / Tempus
Data, sequencing, and clinical decision-support adjacency.
Asset Attractiveness Score
68
Overall partnerability score
Higher scores mean the asset has stronger unmet need, clearer white space, better buyer fit, and a faster path to a value-creating milestone.
Unmet need
How painful and urgent the target market looks.
62/100
Weight 15%Contribution 9 pts
Competitive white space
Whether the asset has room to matter despite existing competitors.
68/100
Weight 15%Contribution 10 pts
Differentiation
How clearly the technology can be positioned as different.
80/100
Weight 15%Contribution 12 pts
Stage / data quality
How much real validation exists today.
52/100
Weight 10%Contribution 5 pts
IP strength
How investable the patent and exclusivity story appears from public data.
58/100
Weight 10%Contribution 6 pts
Development feasibility
How practical the next experiments and regulatory path look.
68/100
Weight 10%Contribution 7 pts
Strategic buyer fit
How naturally the asset fits pharma or platform-company priorities.
80/100
Weight 15%Contribution 12 pts
Near-term value inflection
How quickly a modest spend could create a partnerable milestone.
70/100
Weight 10%Contribution 7 pts
Vetted Vendor Matchmaking
Execution Need
Recommended Partners
Fit
Preclinical CRO
Charles River, WuXi AppTec, Evotec
IND-enabling tox, PK/PD, disease models
Clinical Validation Partner
Medpace, Precision for Medicine, Q2 Solutions
Biomarker validation and sample logistics
Cell/Gene CDMO
Lonza, Catalent, Thermo Fisher
Vector, cell processing, potency assays
Development Roadmap
Phase 1License only after a gated diligence sprint
Validate the pivot thesis: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero. Confirm IP position, inventor data package, core claims, and the cheapest decisive experiment.
Phase 2Retrospective validation plus one pharma pilot
Use banked samples or existing datasets to prove clinical utility before paying for a prospective study.
Phase 3Prospective enrichment study with Medpace
Run the smallest study that proves the tool improves enrollment, stratification, or decision quality.
Phase 4BD auction, option deal, or focused commercial launch
Package the asset around the de-risked milestone: validated biology, manufacturable process, qualified biomarker, or a clinically visible signal.
Strategic Pharma Attractiveness
Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp specialty therapeutics wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.
Likely licenseeRoche Diagnostics
Companion diagnostic and translational biomarker fit.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeThermo Fisher
Research-tool commercialization and pharma services channels.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Likely licenseeIllumina / Tempus
Data, sequencing, and clinical decision-support adjacency.
A focused indication thesis, IP clarity, and one decisive experiment that shows why this belongs in their portfolio.
Best value-creating indicationsa pharma trial-enrichment use case before broad diagnostic commercializationa biomarker-enriched or operationally easy subgroup that can show signal with fewer patientsan adjacent indication where existing pharma assets could create combination or lifecycle value
Best positioned as a de-risked option, sponsored research package, or asset-specific license rather than a broad platform sale. That structure fits how strategic buyers often test early science before committing major capital.
Development Strategy to Increase PoS
First indicationa pharma trial-enrichment use case before broad diagnostic commercialization
Patients already represented in banked samples, trial datasets, or partner registries.
Study designRetrospective locked-dataset validation followed by one prospective pharma enrichment pilot.
Designed to answer the most likely pharma diligence objection before expensive development spend.
Key experimentsValidate the AI-optimized pivot: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zeroRun independent replication of the core claim with pre-specified success criteriaGenerate a partner-facing risk register that separates solved, testable, and unresolved risks
Likely objection
How to answer it
Too early
Answer with a gated option structure and one cheap decisive experiment.
Unclear differentiation
Answer with a competitor map and specific patient-selection or delivery advantage.
Uncertain translatability
Answer with human-relevant models, biomarkers, and computational bridging.
Inflection Point, Exit & Repositioning
Most attractive stagebiomarker validation
Early option/license if buyer fit is obvious; co-development if the technology needs partner assets; spinout only when the asset can support a focused company.
Deal timingLicense or option after the first independent validation milestone; sell or spin out after a stronger translational or early clinical signal.
Independent replication of the core scientific claim · Validated patient-selection, biomarker, dose, or delivery rationale · Partner-ready IP and development gap memo · Execution plan for the AI-optimized path: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero
Trial-enrichment service
Sell into pharma clinical operations before attempting broad reimbursement.
Companion diagnostic option
Attach the technology to a partner drug where patient selection has immediate value.
Final Recommendation
Proceed with repositioning
Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero
Best next experiment
Run the smallest independent study that validates: Use a centralized CDMO, lock the release assay early, and design the first trial around tumor-antigen evidence rather than broad basket ambition.
Best pharma targets
Roche Diagnostics, Thermo Fisher, Illumina / Tempus
Licensing / sale timing
Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.
